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 Abstract 
Pendred syndrome is characterized by sensorineural deafness and post-pubertal goiter. It 
is caused by mutations in the anion exchanger, pendrin (SLC26A4). The purpose of this study 
was to understand the etiology of Pendred syndrome using a mouse model. Different methods of 
amplification from nanogram amounts of starting RNA were evaluated for gene array 
application. Gene arrays were performed and free radical stress markers were compared between 
the stria vascularis and the thyroid of the Slc26a4+/- and Slc26a4-/- mice. Hearing loss in Slc26a4-
/- mice is linked to the loss of Kcnj10 protein expression and consequently the loss of 
endocochlear potential. To understand the mechanism of hearing loss in Slc26a4-/- mice, 
progressive loss of Kcnj10 protein expression in stria vascularis of Slc26a4-/- mice was assessed, 
the modulation of Kcnj10 protein expression by free radical stress in cultured stria vascularis and 
in an heterologous expression system was evaluated. To characterize the thyroid pathology, 
Slc26a4 expression in the thyroid of Slc26a4+/- mice was measured in a developmental study and 
correlated with serum thyroxine (T4) levels of Slc26a4+/- and Slc26a4-/- mice over a 
developmental time course. All tested methods of RNA amplification were suitable for gene 
array application and demonstrated high internal consistency. Intermethod comparisons revealed 
variations in data, suggesting that a single amplification method ought to be used within a given 
experiment. Markers of free radical stress were increased in the stria vascularis of Slc26a4-/- mice 
before the onset of hearing. Progressive loss of Kcnj10 expression was seen in Slc26a4-/- mice at 
the onset of hearing. Furthermore, free radical stress modulated the expression of Kcnj10 in 
cultured stria vascularis and in a heterologous expression system. The Slc26a4 mRNA  
expression was marginal in the thyroid and did not correlate with serum T4 levels. Further, 
absence of Slc26a4 did not affect  free radical stress markers in the thyroid. These data suggest 
that free radical stress-mediated loss of Kcnj10 expression in stria vascularis contributes to 
deafness in the Pendred syndrome mouse model and that  pendrin is not essential for the function 
of mouse thyroid gland.  
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 Abstract 
Pendred syndrome is characterized by sensorineural deafness and post-pubertal goiter. It 
is caused by mutations in the anion exchanger, pendrin (SLC26A4). The purpose of this study 
was to understand the etiology of Pendred syndrome using a mouse model. Different methods of 
amplification from nanogram amounts of starting RNA were evaluated for gene array 
application. Gene arrays were performed and free radical stress markers were compared between 
the stria vascularis and the thyroid of the Slc26a4+/- and Slc26a4-/- mice. Hearing loss in Slc26a4-
/- mice is linked to the loss of Kcnj10 protein expression and consequently the loss of 
endocochlear potential. To understand the mechanism of hearing loss in Slc26a4-/- mice, 
progressive loss of Kcnj10 protein expression in stria vascularis of Slc26a4-/- mice was assessed, 
the modulation of Kcnj10 protein expression by free radical stress in cultured stria vascularis and 
in an heterologous expression system was evaluated. To characterize the thyroid pathology, 
pendrin expression in the thyroid of Slc26a4+/- mice was measured in a developmental study and 
correlated with serum thyroxine (T4) levels of Slc26a4+/- and Slc26a4-/- mice over a 
developmental time course. All tested methods of RNA amplification were suitable for gene 
array application and demonstrated high internal consistency. Intermethod comparisons revealed 
variations in data, suggesting that a single amplification method ought to be used within a given 
experiment. Markers of free radical stress were increased in the stria vascularis of Slc26a4-/- mice 
before the onset of hearing. Progressive loss of Kcnj10 expression was seen in Slc26a4-/- mice at 
the onset of hearing. Furthermore, free radical stress modulated the expression of Kcnj10 in 
cultured stria vascularis and in a heterologous expression system. The pendrin mRNA  
expression was marginal in the thyroid and did not correlate with serum T4 levels. Further, 
absence of pendrin did not affect  free radical stress markers in the thyroid. These data suggest 
that free radical stress-mediated loss of Kcnj10 expression in stria vascularis contributes to 
deafness in the Pendred syndrome mouse model and that  pendrin is not essential for the function 
of mouse thyroid gland.  
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CHAPTER 1 - Introduction 
Organization of this chapter 
This chapter begins with an overview of the ear and of the mechanisms involved in hearing, 
followed by a brief summary of the different types of hearing loss. The  mechanisms involved in 
several genetic and non-genetic forms of sensorineural deafness (defects in cochlea) are 
provided, with a particular emphasis on Pendred syndrome, the subject of this dissertation. The 
clinical features of this disease and the current knowledge about the pathology of this disease as 
obtained from studies on the animal model are summarized. Then, a description of the expression 
and function of pendrin in the pendrin-expressing tissues, stria vascularis and thyroid, is 
provided. The components and mechanisms of free radical stress, which plays a role in many 
forms of sensoineural deafness, are described. Because gene arrays have been a major tool in 
formulating the hypothesis for this dissertation, a brief section on the use and methodology of 
gene arrays is included. Finally, the approaches to be used in achieving the goal of this 
dissertation are outlined. 
Hearing 
Humans are capable of hearing in the frequency range of 20 to 20,000 Hz. Perception of sound is 
a complex process that is performed by the auditory apparatus. The auditory system consists of 
the outer ear, middle ear, inner ear and the auditory cortex in the brain. Sound waves enter the 
outer ear and are transmitted to the middle ear, where the pressure of the sound waves on the 
tympanic membrane is converted into mechanical vibrations. The cochlea then converts the 
mechanical vibrations into electrical signals in the inner ear. These electrical signals are 
transmitted to the auditory cortex, where they are interpreted by the brain (Fig. 1.1). 
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Figure 1.1: Schematic diagram of the auditory apparatus 
The auditory apparatus consisting of outer ear, middle ear, inner ear and the auditory cortex is 
shown.  (For a brief description of the sound transduction mechanism, see text).  
The outer ear consists of the pinna (or auricle) and the outer ear canal and is key to the 
localization of sound. Sound is collected by the pinna, the visible external ear. In humans, the 
pinna is required for comprehension of directionality of sound but is not essential for hearing. 
However, in some animals with a flexible external ear (like the horse), the pinna is indispensable 
for sound localization and amplification. The outer ear canal channels sound waves to the 
tympanic membrane (ear drum) of the middle ear. The outer ear canal also produces cerumin 
(natural wax) that provides a protection from external irritants.  
The middle ear consists of an air-filled tympanic cavity, the tympanic membrane, three 
bony ossicles (malleus, incus and stapes), middle ear muscles and the Eustachian tube. The 
tympanic membrane is a thin, but extremely strong, membrane that is connected to the malleus. 
The incus joins the malleus and the stapes together, forming a chain of levers. Movement of the 
tympanic membrane by sound wave pressure leads to successive movement of the malleus, the 
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incus and the stapes. The stapes contacts the oval window of the cochlea in the inner ear. When 
the stapes moves as a result of sound pressure, it causes fluid movement in the cochlea, which 
subsequently drives sensory transduction. The Eustachian tube joins the tympanic cavity of the 
middle ear to the nasal pharynx and equilibrates the air pressure between the tympanic cavity and 
the external environment. The middle ear plays a key role in the efficient transmission of sound 
energy. In the absence of this complex architecture, most of the sound-associated vibrational 
energy received at the external ear would be dissipated before reaching the inner ear. The 
tympanic membrane has an extremely large surface area compared to the stapes (the smallest 
bone in the body) and this helps in concentrating the energy of the sound waves. Furthermore, 
the lever arrangement of the ossicles leads to an increase in the force applied to the stapes and 
thereby to the fluid spaces in the inner ear.  
The inner ear is encased in the temporal bone and consists of the cochlea (the organ of 
hearing) and the vestibular system (the organ of balance). The cochlea is a snail-shaped structure 
of two and three-quarter turns that spirals around a central bony core (the modiolous). The 
cochlea contains three parallel fluid-filled comparments: scala vestibuli, scala media and scala 
tympani. The scala media forms the cochlear duct, which separates the scala vestibuli from the 
scala tympani and contains the sensory epithelium (Fig. 1.2). The scala vestibuli and the scala 
tympani are filled with perilymph, which resembles most extracelluar fluids with high Na+ (~150 
mM) and low K+ (~5 mM) concentrations. The scala media is filled with endolymph, a unique 
extracellular fluid with an ionic composition similar to intracellular fluid, with high K+ (~150 
mM) and low Na+ (~1.3 mM) concentrations. On one side of the cochlear duct is the stria 
vascularis, which is responsible for the maintainence of the ionic composition and the highly 
positive potential (endocochlear potential, +80mV) of the endolymph. The endocochlear 
potential is the driving force for sensory transduction and is required for the sensitivity of 
hearing. The scala media is separated from the scala vestibuli by the Reissner's membrane and 
from the scala tympani by the basilar membrane. The organ of Corti contains the sensory 
receptor cells (hair cells), faces the scala media and resides on the basilar membrane. The hair 
cells are essentially sandwiched between two extracellular matrices, the tectorial membrane (on 
top) and the basilar membrane (on bottom). The major sensory receptor cells involved in the 
detection of sound are the inner hair cells. The outer hair cells, in conjunction with the tectorial 
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membrane, play a role in the amplification of the movements of the basilar membrane. Fluid 
displacement caused by the vibration of the stapes leads to the oscillatory movement of the 
flexible basilar membrane and alternating depolarization-hyperpolarization of the inner hair 
cells. The basilar membrane decreases in rigidity from the base to the apex of the cochlea, 
so different parts of the cochlea respond to different sound frequencies. High frequency is 
detected at the base of the cochlea whereas low frequency sound is detected at the apex. When 
the basilar membrane oscillates, mechanically gated channels are opened by the displacement of 
stereocilia on top of each inner hair cell, which, with the driving force provided by the 
endocochlear potential, causes an influx of K+ into the inner hair cells. This movement of K+ 
depolarizes the hair cells, consequently opening voltage-gated Ca2+ channels that mediate Ca2+ 
influx and ultimately the release of neurotransmitter from the basal pole of the hair cells. When 
neurotransmitter is released from the inner hair cells, afferent nerves initiate an action potential 
that is sent to the brainstem, where the auditory nerve synapses in the cochlear nucleus. Auditory 
information from the cochlear nucleus is divided into two pathways. First, auditory nerve fibers 
from the ventral cochlear nuclei terminate at the superior olivary nucleus where differences in 
the timing and loudness of sound from each ear is compared to infer the directionality of sound. 
Auditory fibers from the superior olivary nucleus then passes upward to the lateral lemniscus and 
from there project to the inferior colliculus. The second auditory pathway includes auditory 
nerve fibers from the dorsal cochlear nuclei that directly go to the lateral leminscus and from 
there pass to the inferior colliculus. The auditory pathway from the inferior colliculus proceeds 
to the auditory nucleus (medial geniculate nucleus) in the sensory thalamus, and from there is 
projected to the auditory cortex, enabling the perception of sounds.  
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Figure 1.2: Schematic diagram showing the major components of the cochlea that are 
involved in sensory transduction.   
Left: A cross section of the cochlear duct. The perilymph fluid spaces, scala vestibuli and scala 
tympani (blue) are separated by the scala media (cochlear duct, pink).  Also labeled in the 
diagram are the Reissner’s membrane, stria vascularis, sensory hair cells (inner hair cell and 
outer hair cells), sterocilia on the inner hair cell, afferent auditory nerve fibers, the tectorial and 
the basilar membrane.  Right: Magnified view of the hair cell showing the stereocila. (For a 
brief description on the cochlear function, see text).  
Hearing loss  
Deafness is defined as the impaired or complete loss of hearing and affects approximately 
1-5 newborns per 1000 births (34). The onset of deafness can be variable, affecting patients 
either at birth, prelingually or later in adult life. Furthermore, hearing loss can have a sudden 
onset or deteriorate progressively. Hearing loss can be broadly classified into different categories 
depending on the threshold intensity: mild (20-40 dB), moderate (40-70 dB), severe (70-90 dB), 
and profound (> 90 dB).   
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The three major forms of hearing loss are conductive hearing loss, sensorineural hearing 
loss and mixed hearing loss. Conductive hearing loss is due to problems in the outer and middle 
ear that interfere with the efficiency of sound transmission to the cochlea. This type of hearing 
loss can generally be treated without surgery. Sensorineural hearing loss is due to defects in the 
cochlea or the auditory nerve pathway and accounts for approximately 90% of individuals 
affected by deafness worldwide. Mixed hearing loss, as the name implies, is due to a 
combination of conductive and sensorineural defects. 
Inner ear disease mechanisms  
Sensorineural hearing loss due to defects in the cochlea can be caused by genetic 
mutations and/or environmental factors. Genetic forms of hearing loss can be linked to either a 
syndromic disease or can be non-syndromic in presentation, affecting only the cochlea (60).  
Examples of syndromic hearing loss include Usher syndrome (deafness and retinitis 
pigmentosa), Pendred syndrome (deafness and goiter), Jervell and Lange-Nielsen syndrome 
(deafness and long QT intervals), and Alport syndrome (deafness and renal anomalies).  
Examples of genes that are mutated in non-syndromic forms of hearing loss include CX26, 
CX30, CDH23, TECTA, THRB and COCH (46). Non-genetic hearing loss results from a variety 
of causes including noise exposure, contact with organic solvents, drug-induced ototoxicity, viral 
infections, and trauma (9; 18; 20; 21; 51). The risk of acquired hearing loss due to environmental 
exposure may be increased in humans with a genetic mutation. For example, people with 
mutations in 12S rRNA are more likely to develop hearing loss from the use of ototoxic drugs 
than individuals in the general population (17). Apart from factors that affect the inner ear 
directly, sensorineural deafness can also result from congenital systemic hypothyroidism (41; 
65). 
 Mouse models for genetic, as well as environmentally-acquired, hearing loss have been 
critical to the understanding of cochlear pathology in sensorineural hearing loss (19; 43). In most 
cases of sensorineural hearing loss, the primary effect is either sensory (affecting the hair cells), 
metabolic (affecting the stria vascularis), mechanical (affecting the basilar and tectorial 
membrane) or neural (affecting the auditory nerve). Brief descriptions of several common forms 
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of sensorineural hearing loss, and the associated cochlear pathology are presented in the 
following paragraphs. 
Genetic  forms of sensorineural hearing loss 
Ushers syndrome type 1 (USH1): USH1 is an autosomally inherited disease with profound 
congenital hearing loss, vestibular dysfunction and adult onset of retinitis pigmentosa. To date, 
mutations leading to USH1 have been identified in 5 genes: MYO7A, CDH23, PCDH15,  
USH1C and USH1G, (29). Mouse models defective in each of these genes display hearing 
impairment but do not develop retinitis pigmentosa (2). Proteins encoded by these genes, myosin 
VIIa, cadherin 23, protocadherin 15, harmonin and SANS, localize primarily in the hair cell 
sterocilia. Experimental evidence suggest that loss of  hearing results from lack of sterocilliary 
links and disorganized hair cell bundles (12).   
Deafness due to mutations in connexins:  Connexins form the functional unit of intercellular 
channels, gap junctions that electrically couple neighboring cells and provide a conduit for 
metabolite transport. The murine cochlea has an extensive gap junction network with prominent 
expression of five connexin genes: Cx26, Cx30, Cx31, Cx29 and Cx45 (1). Mutations in CX26 
account for almost 50% of cases of non-syndromic hearing loss in childhood (10; 27). Cx26 and 
Cx30 are highly expressed in the cochlea in cells of the organ of Corti and the lateral wall (stria 
vascularis and spiral ligament) (33). Absence of Cx26 and Cx30 in knockout mouse models is 
associated with deafness (7; 64). Hearing loss in the Cx26-/- and Cx30-/- mice may be a 
consequence of cellular death in the organ of Corti and loss of endocochlear potential.  Cx30-/- 
mice fail to develop endocochlear potential, whereas Cx26-/- mice lose the endocochlear potential 
soon after the onset of hearing.  
Environmentally acquired/ non-genetic hearing loss 
Noise-induced hearing loss (NIHL):  NIHL is one of the primary causes of non-genetic 
sensorineural hearing loss (9). Traumatic or constant high level exposure to noise leads to 
increased production of free radical species in the cochlea, necrosis and apoptosis of sensory hair 
cells, reduction in endocochlear potential and damage to cellular structures in both the organ of 
Corti and stria vascularis (22). It has been suggested that free radical stress instigates the 
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observed cochlear pathology in NIHL. This hypothesis is supported by studies in animal models 
that successfully demonstrate protection against NIHL by antioxidant treatment (42). Apart from 
NIHL, free radical stress has been shown to be involved in the mechanisms of hearing loss due to 
drug-induced ototoxicity and aging (51). In both drug-induced ototoxicity (from drugs like 
aminoglycosides or cisplatin) and aging, the primarily affected tissues are either sensory hair 
cells or stria vascularis. Further, antioxidant treatment has also been shown to ameliorate 
aminoglycoside and cisplatin-induced ototoxicity (50; 52).  
Neonatal hypothyroidism: Thyroid hormones are critical for cochlear development, and the lack 
of thyroid hormone due to either genetic or environmental factors during prenatal and early 
postnatal development leads to deafness (28; 58). Cochlear sensitivity to thyroid hormone is 
demonstrated by the fact that maturation of sensory cell-containing organ of Corti is dependent 
on the availability of thyroid hormone (66). Moreover, the tectorial membrane is distended 
during hypothyroidism in mice and the levels of tectorial membrane-specific protein Tectb are 
altered, indicating a role of extracellular matrix in the pathophysiology of deafness (28). In this 
context, it is important to note that loss of another tectorial membrane-specific protein, TECTA,  
leads to deafness in humans (40). The impact of thyroid hormone deficiency in the cochlea is not 
limited to the organ of Corti region. Studies show loss of endocochlear potential, loss of Na+-K+ 
ATPase in stria vascularis  and degeneration of stria vascularis under thyroid hormone deficiency 
(39; 73) 
Menière’s disease: The symptoms of this disease include fluctuating hearing loss, vertigo, 
tinnitus and sensation of fullness in the ear (38). The cause of Menière’s disease is unknown, but 
emotional as well as physical stress is known to trigger the episodic attacks of vertigo and 
hearing loss in affected persons (57; 63). Menière’s disease patients consistently show 
enlargement of the endolymphatic space, leading to the distention of  Reissner’s membrane (44). 
The speculated origins of Menière’s disease include: disturbed fluid homeostasis of the 
endolymph, oxidative stress, hair cell apoptosis, autoimmunity and excitotoxicity (55). 
Tremendous progress has been made toward understanding the causes and pathologies 
for various types of sensorineural hearing loss. However, we numerous genes (eg.,: OTOA, 
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DFNA5) associated with deafness remain incompletely understood due in part to the lack of 
adequate models. As a result, their role in the cochlea remains undefined. (19).   
Pendred syndrome  
Pendred syndrome was first described by Dr. Vaughn Pendred in 1896 (45). It is an 
autosomal recessive disease that affects the inner ear and the thyroid and is caused by loss-of-
function mutations in an anion exchanger, pendrin, (SLC26A4) (15).  
Clinical features  
The clinical features of Pendred syndrome include deafness, enlarged vestibular 
aqueduct, goiter and positive perchlorate discharge test (8). Hearing loss, the most consistent 
pathology of Pendred syndrome, can either be manifested at birth or can develop progressively, 
affecting most patients prelingually (8; 61). In a few cases, hearing loss was documented to have 
been triggered by a slight head injury or mild infection (35). In contrast to deafness, the thyroid 
pathology in Pendred syndrome is variable in nature. Goiter affects most patients after puberty 
and can be either hypothyroid or euthyroid. Clinical tests to evaluate thyroid function include 
measurement of triiodothyronine (T3), thyroxine (T4) and thyroid stimulating hormone (TSH).  
Patients with Pendred syndrome generally show serum TSH, T4 and T3 within normal ranges. 
However, affected members of a family have significantly higher levels of TSH and T3/T4 ratio 
in the serum and significantly lower levels of serum T4 when compared to their unaffected 
siblings (56). Increased levels of serum thyroglobulin have also been reported in patients with 
Pendred syndrome, suggesting that the integrity of the thyroid epithelium may be compromised  
(56). Although Pendred syndrome patients do not have overt balance problems, detailed testing 
in a few clinical studies has revealed vestibular defects (61).  
Animal models  
Investigations of the mechanisms involved in the etiology of Pendred syndrome have 
been greatly assisted by the creation of a mouse model. Wild-type mice as well as Slc26a4+/- 
mice begin hearing at postnatal day 12 (P12) (31; 69). The Slc26a4+/- mice show no symptoms of 
vestibular dysfunction and were used in our study as controls. However, Slc26a4-/- mice never 
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develop hearing and display severe symptoms of vestibular dysfunction by 3 weeks of age (14; 
69). Studies on adult Slc26a4-/- mice have not revealed any thyroid pathology (14).  The loss of 
endocochlear potential has been suggested as the primary cause of deafness in the Pendred 
syndrome mouse model (68).  
Stria vascularis and endocochlear potential  
The stria vascularis is a double-layered epithelium consisting of marginal cells, 
intermediate cells and basal cells. Tight junctions in the marginal cell layer form the barrier 
between the endolymph and the intrastrial fluid, whereas the tight junctions of the basal cell layer 
form the barrier between the intrastrial fluid and the extracellular fluid in the spiral ligament 
(Fig. 1.3). Gap junctions connect basal cells to the spiral ligament fibrocytes and the intermediate 
cells in the stria vascularis. The tight junctions in both layers of the epithelium isolate the stria 
vascularis from the surrounding tissue. This double-layered system is required for the generation 
and maintainence of the endocochlear potential, since the vestibular system, which has only a 
single marginal cell layer, fails to produce an endovestibular potential.  
The endocochlear potential is created by a very low K+ concentration (~1.3 mM) in the 
intrastrial fluid and a high K+ concentration in the cytosol of the intermediate cells. The marginal 
cells contribute to the formation of endocochlear potential by pumping K+ from the interstrial 
space into scala media, thereby maintaining low K+ in the intrastrial fluid. Basal cells help in the 
generation of endocochlear potential by providing K+ to the intermediate cells {reviewed in 
(67)}.  
The K+ channel Kcnj10 is expressed in the intermediate cells of stria vascularis and is 
necessary for the generation of the endocochlear potential. The indispensable role of Kcnj10 in 
the development of endocochlear potential is evident from the observation that Kcnj10-/- mice 
fail to develop an endocochlear potential (37).  
Pendrin expression and function 
Pendrin is primarily expressed in the inner ear, thyroid and kidney (16; 48; 49). Slc26a4 
mRNA expression has also been shown in the mammary gland, testes, endometrium and placenta 
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(4; 32; 47; 62). In heterologous expression systems, pendrin has been characterized as an anion 
exchanger capable of transporting Cl-, HCO3-, I-, and formate  (53; 54; 59).  
Pendrin in the inner ear 
Pendrin expression has been shown in the cochlea, the vestibular labyrinth and the 
endolymphatic sac (16). In the cochlea, pendrin is expressed in the outer sulcus cells, root cells, 
spiral prominence epithelium and the spindle cells of stria vascularis (Fig. 1.3A) (68). The 
absence of pendrin leads to a more acidic endolymph in the Pendred syndrome mouse model, 
suggesting a role of pendrin in bicarbonate secretion and cochlear pH homeostasis (69). Pendrin 
is reportedly involved in bicarbonate transport in the renal collecting duct (49), which supports 
the hypothesis that pendrin contributes to the cochlea pH regulation. 
           Although normal K+ concentration has been observed in the endolymph of adult Slc26a4-/- 
mice, the endolymphatic spaces were enlarged prenatally, suggesting an increased rate of K+ 
secretion from the stria vascularis (14; 68). Further, the endocochlear potential that is generated 
by stria vascularis and is required for the sensitivity of hearing is progressively lost in Slc26a4-/- 
mice (69). In the stria vascularis, Kcnj10 protein expression is greatly reduced at P15 (69) (Fig. 
1.3B). Although pendrin is only marginally expressed in stria vascularis, the cochlear pathology 
in Slc26a4-/- mice indicates that the loss of stria vascularis function may underly deafness in the 
Pendred syndrome mouse model. However, the mechanism by which loss of pendrin can affect 
Kcnj10 protein expression in stria vascularis and thereby endocochlear potential has not yet been 
established. 
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Figure 1.3: Localization of pendrin and Kcnj10 in Slc26a4+/- and Slc26a4-/-mice. 
 A, B) Pendrin expression in the cochlea.  Pendrin is mainly expressed in spiral prominence 
epithelial cells (SP), root cells (RC) and in outer sulcus epithelial cells (OS) and spindle cells 
(SC) (green). Figure was adapted from Wangemann et al., 2004.  C) Kcnj10 protein expression 
is lost in the cochlea of Slc26a4-/- mice. Schematic diagram showing the different cellular 
localization of pendrin (green) and Kcnj10 (blue) in the cochlea of  Slc26a4+/- mice (left). In the 
Slc26a4-/- mice that lack pendrin, expression of Kcnj10 is lost in the stria vascularis (right). 
Moreover, the Slc26a4-/- mice have an enlarged endolymphatic space and no endocochlear 
potential.  Also note that in the stria vascularis (SV), the strial marginal cells (SMC) and the 
basal cell  (BC) are interconnected between themselves by tight junctions thereby forming two 
barriers. (Other abbreviations used in the figure: LIM: Spiral limbus, RM: Reissner’s 
membrane, SL: Spiral ligament)  
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Pendrin in the thyroid 
In the thyroid, pendrin is expressed in the apical membrane of thyrocytes (5). Pendrin has 
been shown to mediate iodide efflux in vitro in mammalian cells (71). Iodide organification 
defects observed in patients with Pendred syndrome strongly suggest that pendrin is the apical 
iodide transporter in the thyroid (48). A schematic diagram depicting organification of iodide in 
the thyroid gland is shown (Fig. 1.4). However, the thyroid likely has alternative pathways for 
apical iodide transport, since the absence of pendrin leads to only partial defects in iodide 
organification. In adult mice, no differences in the serum T3, T4 and TSH levels were observed 
between  Slc26a4+/+ and Slc26a4-/- mice,  indicating that pendrin is not necessary for thyroid 
hormone production (14).   
 
Figure 1.4: Schematic diagram showing iodide organification in the thyroid.  
Pendrin is expressed in the apical membrane of the thyroid follicular cells and may be the apical 
iodide efflux pathway.  (Note: TPO indicates the thyroid peroxidase). 
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Thyroid gland function 
The thyroid consists of two lobes that are located on either side of the trachea.  The 
functional unit of the thyroid gland and site of production of thyroid hormone is the follicle, a 
protein-rich colloid (predominantly made up of thyroglobulin) surrounded by follicular cells. 
The process of thyroid hormone production is shown in Fig. 1.4 and Fig. 1.5. Iodide is 
taken up from the blood into the follicular cells of the thyroid gland by the basolatarally located 
transporter, Na+/ I- symporter, NIS.  Iodide is then transported across the apical membrane of the 
follicular cell by a yet-to-be-identified transporter (pendrin is a candidate protein for this role). 
At the apical membrane of the follicular cells, iodide is oxidized by hydrogen peroxide, H2O2, in 
a reaction that is catalyzed by the thyroid peroxidase (Tpo). Oxidation of iodide leads to the 
formation of various intermediate species: hypoiodate (OI-), hypoiodous acid (HOI) or iodinium 
(I+). These species are incorporated into the tyrosine residues of the thyroid hormone precursor 
thyroglobulin to form mono-iodotyrosine (MIT) and di-iodotyrosine (DIT).  The MIT and DIT 
thyroglobulin complexes are taken up into the colloid where T4 thyroglobulin and T3 
thyroglobulin complexes are formed. The major coupling reaction is between two DIT 
molecules, which combine to form the T4 thyroglobulin complex.  Coupling can also take place 
between a DIT and a MIT molecule to form the T3 thyroglobulin complex. The T3 and T4 
thyroglobulin complexes are taken up into the follicular cells by pinocytosis. Within the 
follicular cells, hydrolysis of T3 and T4 thyroglobulin complexes in the lysosomes releases 
unbound T3 and T4. A small amount of T4 is further converted into T3 in the follicular cells by 
the action of cellular deiodinases (Dio1 and Dio2).  Finally, the thyroid hormones (T3 and T4) 
are released into the blood.  
The primary form of thyroid hormone produced and secreted by the thyroid gland is T4 
whereas the biologically active form of thyroid hormone that is utilized in cells is T3. Target cell 
membranes have thyroid hormone transporters that mediate the cellular uptake of thyroid 
hormone from the blood (Fig. 1.5). Once within the cell cytosol,  T4 is converted by the cellular 
enzymes Dio1 and Dio2 to T3, which is the the biologically active form of thyroid hormone (T3) 
(3; 24; 70). 
 15
 
Figure 1.5: Schematic diagram showing production, secretion and cellular metabolism of 
thyroid hormone.  
Left: The thyroid hormones, T4 and T3, are produced in the follicular cells of the thyroid gland  
and released into the blood.  Right: T4  is taken up by a cell within the target tissue and 
converted to the biologically active form, T3.  (Abbreviations used: DIT, diiodotyrosine, MIT: 
monoiodotyrosine, Tg: thyroglobulin, TRE: thyroid hormone responsive element, TR: thyroid 
hormone receptor) 
The metabolic activity of virtually every cell in the body is governed by thyroid 
hormones. Thus, the  strict control of their production and availability is indispensable to body 
function. The maturation and development of a number of tissues, including the cochlea, requires 
thyroid hormones during a specific time frame. In rats, the crucial time period in which the 
cochlea is sensitive to thyroid hormone begins embryonically with the onset of thyroid gland 
function at embryonic day 17 (~ E17) and continues until the onset of hearing at ~P12. Unlike 
hypothyroidism acquired in adulthood, the symptoms of which are reversible after treatment, the 
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lack of thyroid hormone during early development results in  permanent deafness. Correcting 
thyroid hormone levels after the period of thyroid hormone sensitivity does not restore hearing 
(11; 66).   
The production and secretion of thyroid hormone by the thyroid gland varies during 
development. In the mouse, the levels of T4 in the serum peak between P10 and P15, then 
decrease gradually until P21 (weaning) before peaking again to reach adult levels around puberty 
(6).  
While evaluating thyroid gland function in Pendred syndrome, it would be important to 
consider the time points of maximal thyroid hormone requirement in the cochlea and the time 
points of maximal thyroid hormone production by the thyroid gland. It is possible that the 
absence of pendrin during developmentally critical time points leads to transient hypothyroidism 
in the Pendred syndrome mouse model. 
Free radical stress 
Free radicals are highly reactive molecules due to the presence of an unpaired electron. 
The term ‘free radical stress’ refers to levels of reactive oxygen and nitrogen species, either 
radicals or non-radicals, in excess of those compatible with health. The majority of free radical 
production occurs during mitochondrial energy metabolism. Free radicals have important 
functions under physiological conditions. They can act as cell signaling molecules. Macrophages 
and phagocytes utilize free radicals to defend against bacterial invasion.  In health, a balance 
exists between the production of free radicals and their removal by antioxidant defenses. In 
disease, either the level of production of free radicals is increased or the function of the 
antioxidant defense system is compromised. Either disruption thus leads to elevated levels of free 
radicals and free radical stress {reviewed in (13)}. 
Free radical stress can be extremely damaging to tissues. Free radicals can promote tissue 
injury, inflammation and increased cellular death, each of which in turn can increase the 
production of free radicals. Left uncontrolled,  a vicious circle that can lead to tissue destruction 
results (72). As mentioned previously in the section on inner ear disease mechanisms, free 
radical stress has been implicated as the cause of hearing loss in drug-induced ototoxicity and 
 17
noise-induced hearing loss. Increased levels of reactive oxygen species have also been linked to 
the pathology of thyroid tumorigenesis and goiter formation (22; 30; 52; 26). Moreover, 
oxidative stress has been associated with reduced Kcnj10 expression in other systems including 
ischemia-reperfusion injury to the retina and spinal cord of SOD1-G93A mutant mice (23; 25).  
It is concievable that loss of pendrin leads to increased oxidative stress in the stria vascularis and 
the thyroid. Furthermore, increased levels of free radical stress in stria vascularis of Slc26a4-/- 
mice could be responsible for the observed loss of Kcnj10 protein expression (Fig. 1.3B).  
Gene array 
The development of the gene array technology has provided scientists with the ability to 
study the concurrent expression of a large number of genes in a genome at the same time. The 
evaluation of differential gene expression between stria vascularis of Slc26a4+/- and Slc26a4-/- 
mice would facilitate identification of the biochemical pathway that leads to hearing loss in 
Pendred syndrome.  
A typical gene array platform (gene chip) consists of cDNA or gene-specific 
oligonucleotides attached in extremely high density to a glass microscope slide or silicon wafer.  
cRNA or cDNA from a sample is hybridized on the chip and the amount of cDNA bound to each 
oligonucleotide probe is evaluated. The amount of binding detected is taken as representative of 
the level of gene expression in the original sample. Tissue samples that are obtained by 
microdissection (example: stria vascularis and mouse thyroid), laser capture microscopy and 
needle biopsy do not yield sufficient RNA to be used directly in a gene array experiment. RNA 
amplification methods are generally used for producing microgram amounts of RNA from these 
samples before they are hybridized on the gene chip. The quality of the starting RNA and the 
reliability of the amplification method in truly representing the original sample determine the 
quality of the gene array data.   
Current study 
To understand the etiology of Pendred syndrome in a mouse model we took the following 
3 experimental approaches (illustrated in Fig. 1.6 and Fig. 1.8): 
 18
1) Different RNA amplification methods were evaluated for application in gene array analyses.  
The ability to obtain robust amplification of array-caliber RNA from nanogram amounts of 
starting material allowed the production of gene arrays yielding excellent data quality.  Gene 
arrays were performed on RNA isolated from stria vascularis of Slc26a4+/- and Slc26a4-/- 
mice before the onset of hearing at P10 as well from stria vascularis of Slc26a4+/- and 
Slc26a4-/- adult mice. The data obtained from the gene array experiments were submitted to 
the Gene Expression Omnibus (GEO) database (GSE10587 and  GSE4749). Analogous 
analyses were also carried out on thyroid gene arrays obtained from Slc26a4+/- and Slc26a4-/- 
mice at P15, the time of maximal thyroid gland activity (GSE10589). Gene expression 
changes were evaluated between the stria vascularis and thyroid of Slc26a4+/- and Slc26a4-/- 
mice and the results were used to guide further studies.     
 
Figure 1.6: Flow chart illustrating the experimental approach used to evaluate a cause of 
deafness in Pendred syndrome mouse model. 
 
2) Markers of free radical stress were compared between the stria vascularis of Slc26a4+/- and 
Slc26a4-/- mice in a developmental study of the following ages: P10 (before the onset of 
hearing), P15 (after the onset of hearing), P35 (adolescence) and P80 (young adults). The 
levels of Kcnj10 protein expression were compared between P10 and P15 in Slc26a4+/- and 
Slc26a4-/- mice to correlate the levels of Kcnj10 protein with the onset of hearing. We also 
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investigated the ability of free radical stress-inducing agents to modulate the expression of 
Kcnj10 protein in organ cultures of stria vascularis and in a heterologous expression system.  
Because pendrin and Kcnj10 are expressed in different cells (Fig. 1.3), the decreased 
expression of the latter can not be the direct result of the lack of pendrin. A previous study 
from our laboratory demonstrated an increased pigmentation in the stria vascularis of adult 
Slc26a4-/- mice, suggesting free radical stress. In our present data from gene arrays on mouse 
stria vascularis, we found increased levels of Trf expression and decreased levels of Tfrc 
expression which is consistent with the presence of iron-mediated oxidative stress in the stria 
vascularis of Slc26a4-/- mice.   
The enlarged endolymph in the Slc26a4-/- mice maintains the typical K+ 
concentration. This might require increased rate of K+ secretion from stria vascularis.  An 
increased rate of ion transport has been correlated with energy metabolism in the stria 
vascularis (36). Higher metabolism could serve as a source of free radical stress. Free radical 
stress could also be a consequence of reduced intracellular pH of strial marginal cells, an 
implicit consequence of endolymph acidification. In Slc26a4-/- mice, increased oxidative 
stress could diminish Kcnj10 expression and thereby dissipate the endocochlear potential, 
resulting in deafness. We hypothesized that free radical stress could link the absence of 
pendrin with the loss of Kcnj10 in the Pendred syndrome mouse model (Fig. 1.7).   
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Figure 1.7: Hypothesis 
 A graphical depiction of the sequence of events in the cochlea during development of A) 
Slc26a4+/+ mice and B) Slc26a4-/- mice. Pendrin expression that begins at embryonic day 13 
(E13) in Slc26a4+/+ mice is absent in Slc26a4-/- mice. Development of endochlear potential and 
Kcnj10 expression does not parallel the wild-type mice and is progressively lost before the onset 
of hearing at P12 . The Slc26a4-/- mice never develop hearing. We hypothesize that increased 
free radical stress in the stria vascularis depicted in B leads to loss of Kcnj10 protein expression 
and consequently leads to the failure of maintainence of endocochlear potential. In the absence 
of endocochlear potential Slc26a4-/- mice are deaf.   
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3) To determine whether transient systemic hypothyroidism was present in Slc26a4-/- mice, the 
serum T4 levels were measured at various ages and the expression of genes involved in 
thyroid hormone synthesis were evaluated. In order to know if pendrin expression in the 
thyroid is correlated to the serum T4 levels, particularly during the adolescent peak in serum 
T4 levels around P15, we performed a developmental study on thyroids from Slc26a4+/- 
mice. Furthermore, certain markers of free radical stress were compared between the 
thyroids of Slc26a4+/- and Slc26a4-/- mice (Fig. 1.8).  
Everett and co-workers reported normal thyroid gland function and histology in adult 
Slc26a4-/- mice.  However, the thyroid gland activity in mice peaks at approximately P15, 
raising the possibility of transient hypothyroidism early in development.  Moreover, the fact 
that thyroid hormone synthesis requires the production of H2O2, a reactive oxygen species, 
taken together with our measurements indicating increased levels of free radical stress in the 
stria vascularis, led us to test for the presence of oxidative stress in the thyroid of Slc26a4-/- 
mice. 
 
Figure 1.8: Flow chart illustrating the experimental approach used to evaluate the thyroid 
pathology in the Pendred syndrome mouse model. 
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CHAPTER 2 - Microarray-based comparison of three amplification 
methods for nanogram amounts of total RNA 
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Abstract 
Gene expression profiling using microarrays requires microgram amounts of RNA, which 
limits its direct application for the study of nanogram RNA samples available from 
microdissection, laser-capture microscopy or needle biopsies. A novel system, based on Ribo-
SPIA™ technology, has recently been introduced (RS, Ovation-Biotin amplification and labeling 
system, NuGEN Technologies, San Carlos, CA). The utility of the RS system, an optimized 
prototype system for picogram RNA samples (pRS, NuGEN Technologies), and two T7-based 
systems involving one or two rounds of amplification (OneRA, Standard Protocol, Affymetrix, 
Santa Clara, CA or TwoRA, Small Sample Prototcol, Version II, Affymetrix) were evaluated.  
Mouse kidney (MK) and universal reference (MUR) RNA samples, 0.3 ng to 10 µg, were 
analyzed by high-density Affymetrix Mouse 430 2.0 GeneChip® arrays. Call concordance 
between replicates, correlations of signal intensity, signal intensity ratios, and minimal fold-
increase necessary for significance, were determined. All systems amplified partially overlapping 
sets of genes with similar signal intensity correlations. pRS amplified the highest number of 
genes from 10-ng RNA samples.  24 of 26 genes verified by RT-PCR were detected in samples 
prepared by pRS. TwoRA yielded somewhat higher call concordances than RS and pRS (91.8% 
versus 89.3% and 88.1%, respectively). In conclusion, although all target preparation methods 
were found suitable, pRS amplified the highest number of targets and was found to be suitable 
for amplification of as little as 0.3 ng total RNA. In addition, RS and pRS were faster and 
simpler than the T7-based methods and resulted in the generation of cDNA, which is more stable 
than cRNA. 
Keywords 
Gene expression microarray analysis; microdissection; nucleic acid amplification techniques 
Introduction 
Microarrays provide a widely accepted method for gene expression profiling on a 
genome wide scale. Affymetrix GeneChip® microarrays consist of oligonucleotide probes 
presented on a chip for hybridization to biotin-labeled cDNA or cRNA targets prepared from 
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sample RNA (11). Hybridization is detected as fluorescence after binding to labeled streptavidin.  
Gene expression profiling using GeneChip arrays require amplification of sample RNA 
irrespective of the available amounts of RNA. The Affymetrix Standard Protocol, which is well-
established for the preparation of cRNA targets from microgram amounts of total RNA, consists 
of one round of T7 amplification (OneRA) to generate biotin-labeled targets. Gene expression 
profiling of small tissue samples obtained by micro-dissection, laser-capture microscopy or 
needle biopsy that yield mere nanograms of RNA requires amplification either of the 
hybridization signal (8; 20) or of the starting material. Methods for amplification of the starting 
material consist of exponential amplification by PCR (7; 13; 16; 22) and linear amplification 
with multiple rounds of T7 polymerase (1; 3; 4; 9; 15; 21). T7-based linear amplification systems 
have been used widely for amplification and production of cRNA targets. The Affymetrix Small 
Sample Protocol consists of two rounds of amplification (TwoRA) including biotin-labeling and 
is a well-established T7-based method for the preparation of cRNA targets from nanogram 
amounts of RNA (4). A novel linear amplification method, Ribo-SPIA™, which enables mRNA 
amplification in a simple and rapid procedure, has been introduced recently (NuGEN 
Technologies, San Carlos CA) (2; 5). Two systems based on this novel amplification technology, 
the Ovation Biotin System (RS) and a prototype system designed for target preparation from 
subnanogram level total RNA samples (picogram Ribo-SPIA™ prototype system, or pRS), were 
evaluated and compared with the T7-based single and two round amplification systems. The 
Ribo-SPIA systems have several advantages. Sample preparation can be performed within one 
day, which is much faster than the twenty-plus hrs required for TwoRA. Further, RS and pRS 
yield cDNA, which is more stable than cRNA and eliminates biases in microarray results due to 
RNA degradation (19). The present study was designed to evaluate target populations generated 
by the Ribo-SPIA™ based systems and the T7-based systems. Targets were analyzed by high-
density Affymetrix Mouse 430 2 GeneChip®. Evaluation was based on direct comparisons and 
differential gene expression and included call concordances, signal correlations and sensitivities. 
Detection of a limited set of targets was verified by RT-PCR.  
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Materials and Methods 
Target preparation 
Mouse kidney (MK) total RNA (Ambion, Austin, TX) and mouse universal reference 
(MUR) total RNA (Stratagen, La Jolla, CA) were chosen as sources for RNA to minimize 
biological variation and inter-experimental differences. Targets were prepared by four different 
methods: 1) one round of amplification (OneRA), 2) two rounds of amplification (TwoRA), 3) 
Ribo-SPIA linear amplification with the Ovation biotin system (RS), and 4) Ribo-SPIA linear 
amplification with the pictogram Ribo-SPIA prototype system (pRS). 
One Round of Amplification 
Starting with 10 µg of total RNA, cRNA targets were prepared by OneRA (Standard 
Protocol, Version-VII, https://www.affymetrix.com/support/downloads/manuals/expression_s2_ 
manual.pdf, Affymetrix, Santa Clara, CA; Fig. 2.1). Briefly, RNA was transcribed into cDNA by 
reverse transcriptase using a T7-primer that contains a promoter for DNA-dependent RNA 
polymerase (3; 21). Following RNase H-mediated second-strand cDNA synthesis, the double-
stranded cDNA is purified and serves as a template in the subsequent in vitro transcription (IVT) 
reaction. The IVT reaction is carried out in the presence of T7 RNA polymerase and a 
biotinylated nucleotide analog/ribonucleotide mix for cRNA amplification and biotin labeling. 
The biotinylated cRNA targets are then cleaned up, fragmented, and hybridized to GeneChip 
expression arrays. 
Two Round of Amplification  
Starting with 10 ng of total RNA, cRNA targets were generated by TwoRA (Small 
SampleProtocol, Version II, Affymetrix; Fig. 2.1). Briefly, in vitro transcribed cRNA, generated 
by the first round of amplification (see above) was subjected to a second round of amplification. 
cRNA was transcribed into cDNA using random primers and subsequently removed by heat-
induced fragmentation. A second cDNA strand was synthesized using a T7-primer.  A second 
cDNA strand was synthesized using a T7-primer to generate a dscDNA template containing the 
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T7 promoter sequence. The resulting dscDNA was then amplified and labeled using a 
biotinylated nucleotide analog/ribonucleotide mix in the second IVT reaction. The labeled cRNA 
was then cleaned up, fragmented, and hybridized to GeneChip expression arrays.  
 
Figure 2.1: Schematic representation of target preparation using one (OneRA) and two 
(TwoRA) rounds of amplification. RNA is shown in blue and DNA is shown in pink.   
Ribo-SPIA™ Linear Amplification  
Ribo-SPIA™-based RNA amplifications and target preparations were carried out 
according to manufacturer’s instructions (picogram Ribo-SPIA™ prototype system, pRS and 
OvationTM Biotin System, RS, see http://www.nugeninc.com/technology/index.shtml, Nugen, 
San Carlos, CA; Fig. 2.2). Briefly, RNA was reverse transcribed into cDNA by reverse 
transcriptase using a DNA/RNA chimeric primer that is part DNA and part RNA. RNA was 
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degraded by heat and fragments served as primers for second strand synthesis, yielding a double 
stranded cDNA with an RNA/DNA heteroduplex at one end. The RNA portion of the 
heteroduplex portion of the dscDNA, were digested by RNAse H added to the reaction mixture 
together with a DNA polymerase and a second chimeric cDNA/cRNA primer (amplification 
primer).  Amplification proceeds by primer extension, strand displacement and degradation of 
the RNA portion of the primer extension product hybridized to the target to reveal part of the 
priming site for subsequent primer hybridization and extension by strand displacement DNA 
synthesis.  Accumulated cDNA amplification products were fragmented and labeled to generate 
biotinylated cDNA targets. cDNA targets were prepared by RS starting with 100, 30, 10 or 3 ng 
of total RNA or by pRS starting from 10, 3 or 0.3 ng of total RNA. 
 
Figure 2.2: Schematic representation of target preparation using Ribo-SPIA™ linear 
amplification (RS, Ovation-Biotin amplification and labeling system; and pRS, picogram 
RNA samples ). RNA is shown in blue and DNA is shown in pink. 
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Table 2.1: GeneChip array quality metrics (Averge ± SD). 
Values are averages ± SD. OneRA, one round of amplification; TwoRA, two rounds of 
amplification; RS, Ribo-SPIA technology; pRS, pictogram RNA samples. 
Method 
Number of 
Chips 
Scale 
Factor 
Average  
Call All 
Percent 
Present Call 
Background 
Intensity 
Noise Raw Q 
OneRA 6 3.5 ± 0.6 696.5 ±   7.8 45.4 ± 4.0 42.6 ±  2.0 2.6 ± 0.2 1.4 ± 0.1 
TwoRA 6 2.4 ± 0.2 698.0 ±   7.8 46.7 ± 2.5 47.2 ±  2.8 3.0 ± 0.2 1.5 ± 0.1 
RS 15 4.1 ± 0.7 685.7 ±  19.8 43.6 ± 2.0 46.0 ±  5.5 2.9 ± 0.7 1.5 ± 0.2 
pRS 12 2.0 ± 0.3 712.1 ±  27.9 51.3 ± 3.8 74.4 ±12.7 3.9 ± 0.6 2.5 ± 0.3 
 
Table 2.2: Verification of GeneChip array data obtained from MUR RNA. 
Targets were selected according to a set of criteria to ensure fair comparison between TwoRA 
and RS (see MATERIALS AND METHODS). Targets called present or absent in all three 
replicates are marked P or A, respectively. Targets variably called present or absent are marked 
with asterisk. 
Gene Symbol 
Affymetrix # 
 
Average 
Intensity 
OneRA 
 
Average 
Intensity 
TwoRA 
 
Average 
Intensity
RS 
 
Average
Intensity
pRS 
 
Left Primer 
Right Primer 
Expected 
Product 
Size 
Observed
Product 
Size 
RT-
PCR 
Result 
Cdkn1a 
1421679_a_at 
128 
A 
1252 
P 
302 
A 
1415 
P 
ccgtggacagtgagcagtt 
gagtgcaagacagcgacaag 286 279 P 
Nck1  
1421487_a_at 
584 
A 
826 
P 
117 
A 
205 
P 
tttggaaccatctcctccac 
gcccaatgcagtaaacagtc 254 248 P 
Nme3  
1448905_at 
262 
A 
531 
P 
7 
A 
165 
P 
aagctggtggcactgaagctag 
cgagtcgctgccatgaattac 266 270 P 
Cpsf1 
1417665_a_at 
3330 
P 
3990 
P 
184 
A 
827 
P 
gcccatgcaagaaaagacat 
ggtctgtctccagccaagtc 267 275 P 
Ruvbl2 
1422482_at 
2858 
P 
2752 
P 
166 
A 
478 
P 
ggaccgcttgctcattgtat 
gtactgtgtggagcgggatt 275 276 P 
Hrmt1l1 
1416844_at 
1833 
P 
2311 
P 
48 
A 
243 
* 
acccactgtgacatccacac 
gcatcaaggacaccactgac 262 269 P 
Tce2 
1421971_a_at 
1980 
P 
1974 
P 
207 
A 
387 
P 
atgtaccacgattggcgttt 
cacaggacctctctgccagt 283 275 P 
Prkcsh 
1416339_a_at 
2563 
P 
1828 
P 
162 
A 
764 
P 
gacgagctgtagcctgaacc 
tcatccatttatctcccacca 287 279 P 
1110035H23Rik 
1416315_at 
1210 
P 
1273 
P 
99 
A 
191 
P 
agcaaaggtgattcctggtg 
cactggagagagctgatgga 271 268 P 
Pold1 
1448187_at 
1480 
P 
1238 
P 
108 
A 
260 
P 
ctgcccatcgacactcagta 
gtcttgcatcgtgtgtggtc 146 137 P 
Nxph3 
1419710_at 
900 
P 
1082 
P 
136 
A 
68 
A 
actgaggctgaaatggcaac 
aggtggttagggcagaggat 257 256 P 
Nsd1 
1420882_a_at 
1132 
P 
882 
P 
111 
A 
438 
P 
ggagttccagtgctccttca 
gcccatgtgtcctctgctat 273 271 P 
Slc22a5  
1450395_at 
677 
P 
667 
P 
101 
A 
180 
P 
ggggagtttgtttgtttgtca 
caccgatgtgacacgactg 291 298 P 
Lmnb2  
1448531_at 
334 
A 
313 
A 
1092 
P 
636 
P 
aacctccagaacccaccag 
cactccgggtaaccatctca 251 243 P 
Hspa4  
1416147_at 
343 
A 
146 
A 
1081 
P 
170 
P 
cagttgggtgtaggcatggt 
gtcggcaatgaggtgttctt 299 293 P 
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Gene Symbol 
Affymetrix # 
 
Average 
Intensity 
OneRA 
 
Average 
Intensity 
TwoRA 
 
Average 
Intensity
RS 
 
Average
Intensity
pRS 
 
Left Primer 
Right Primer 
Expected 
Product 
Size 
Observed
Product 
Size 
RT-
PCR 
Result 
Neu3  
1419339_at 
83 
A 
22 
A 
536 
P 
539 
P 
gcccttatc cttccaataatgc 
cagtgttagaatgtccccctgg 294 297 P 
Foxc2 
1416693_at 
898 
P 
355 
A 
3582 
P 
4382 
P 
gggacccctaatgacttctg 
ttaaaggctctgggcaagaa 124 123 P 
Hoxc4 
1422870_at 
357 
A 
275 
A 
2844 
P 
942 
P 
ccccatctctttccttaggc 
taaccacgatgagggtaggg 271 259 P 
Tle3 
1419654_at 
382 
P 
42 
A 
2146 
P 
1998 
P 
acagcgaggattttctgtgg 
aaaagcacccacaccagttg 300 293 P 
Max 
1423501_at 
215 
A 
151 
A 
2001 
P 
2268 
P 
tcctccctcacctctgtttg 
ctgcaaatctgtccccactt 197 185 P 
Dusp10 
1417163_at 
204 
A 
93 
A 
1889 
P 
2339 
P 
gacctggaactgactgcaca 
tagcctgtctccccagagaa 138 138 P 
Tcp1-rs1 
1425195_a_at 
1051 
P 
326 
A 
1340 
P 
1110 
P 
atcctctgggagcatctgg 
ggtcctctggtttccctttc 214 217 P 
Akt3 
1422078_at 
369 
P 
65 
A 
1304 
P 
795 
P 
attgcctgcgttttcttttg 
cctctcacatccatcccttg 220 220 P 
Hspa4 
1416147_at 
343 
A 
146 
A 
1081 
P 
170 
P 
cagttgggtgtaggcatggt 
gtcggcaatgaggtgttctt 299 294 P 
Zfp235 
1449329_at 
70 
A 
66 
A 
889 
P 
645 
P 
agctggtgattggcagaac 
tgggtagcactatgcctcaa 255 59 P 
Pik3r1 
1425515_at 
309 
P 
43 
A 
677 
P 
1289 
P 
tcatgtgtcagaaggcagga 
cccaaccctcccacttctat 287 290 P 
Quantification and quality assessment of RNA, cRNA and cDNA  
Quantities of total RNA, cRNA and cDNA were determined by absorbance 
spectrophotometry (ND-1000 Spectrophotometer, Nanodrop Technologies, Rockland, DE). For 
total RNA and for cRNA the conventional conversion, 1 OD260 = 40 ng/µl, was used. For 
cDNA the manufacturer’s recommended conversion, 1 OD260 = 33 ng/µl, was used (Nugen). 
Quality of total RNA (eukaryotic total RNA nano assay) and of cRNA and cDNA (mRNA smear 
nano assay) was determined by microfluidic electrophoresis (Bioanalyzer, Agilent Technologies, 
Palo Alto, CA). 
Microarray analysis  
Hybridizations of cRNA and cDNA targets were carried out according to manufacturer’s 
recommended procedures on high-density oligo-nucleotide gene chips (Mouse 430 2 expression 
array, see http://www.affymetrix.com/support/technical/datasheets/mogarrays_datasheet.pdf, 
Affymetrix). A total of 39 target preparations were performed and each preparation was analyzed 
by one GeneChip® array. Data were scaled to a target intensity of 500 (GCOS software, 
Affymetrix). Normalization quality controls including scaling factors, average intensities, present 
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calls, background intensities, noise and raw Q values were all within acceptable limits (Table 
2.1). Hybridization controls, BioB, BioC, BioD and CreX, were called present on all chips and 
yielded the expected increases in intensities. Analyses of target populations were supported by 
GeneSpring (Silicon Genetics, Redwood City, CA), Excel (Microsoft, CA) and Origin 6.0 
(OriginLab, Northampton, MA). Microarray data were deposited at NCBI GEO accession 
number #GSE1435 and #GSE2019.  
Call concordance 
Probe sets are either called present (P), absent (A) or marginal (M) based on detection p-
values (P: p-value < 0.05, M: p-value 0.05-0.065, A: p-value > 0.065). Nine field P/A/M 
matrices comparing data from two chips were constructed (Origin 6.0). Call concordance was the 
sum of the three concordant fields (P-P, A-A and M-M) and call discordance was the sum of the 
other six fields (P-A, A-P, P-M, M-P, A-M, M-A). Data were expressed as percentage of the 
total number of probe sets (n = 45,101). Call concordance within a set of triplicate data was 
computed as average ± SD of three pair-wise comparisons. Call concordance between two sets of 
triplicates was computed as average ± SD of all nine pair wise comparisons.   
Signal correlation 
Signal intensities without regard to present, absent or marginal calls were correlated and 
linear correlation coefficients (r) were determined (Origin, version 6.0). Correlations r values 
within a set of triplicates were reported as average ± SD of the three possible correlations.  
Correlations r values between two sets of triplicates were based on averaged intensities and 
reported as a simple r value.    
Sensitivity 
Sensitivity was evaluated from the estimated fold-change necessary for significance 
(Foldsig). Foldsig was obtained according to Foldsig = (Avg + 2.776  x √ ( 2 / 3 x SD2)) / Avg 
where Avg and SD are the average and standard deviation of the signal intensity of genes that are 
called present in all replicates, 2.776 is the t-value at p=0.05, assuming 4 degrees of freedom.   
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Differential gene expression 
Signal intensity ratios of genes detected present in all targets prepared from 10 µg and 10 
ng MK and MUR RNA by OneRA, TwoRA, RS and pRS were calculated from averages of 
triplicates. Ratios were correlated between amplification systems and correlations coefficients 
were obtained. 
Verification of microarray data 
A small number of gene targets amplified from MUR RNA and detected by microarray 
were verified by performing RT-PCR (Table 2. 2). Targets were chosen based on gene array data 
obtained from 10 ng MUR RNA amplified by either TwoRA or RS. For each method, 13 targets 
were selected based on a set of six criteria established to assure fair selection between these two 
methods: 1) Targets must be called present in three replicates of the considered amplification 
method (TwoRA or RS). 2) Targets must be called absent in three replicates of the other 
amplification method. 3) Hybridization intensities of the three replicates of the considered 
amplification method must be >100. 4) Targets of the considered amplification method must be 
annotated by Affymetrix as full-length mRNA and not as expressed sequence tag. 5) 
Hybridization intensities must be comparable between sets of chosen targets. 6) Fold-differences 
between called present by one amplification method and absent by the other method must be 
comparable between sets of chosen targets. Average intensities and calls for the 26 selected 
genes are given in Table 2.2 not only for TwoRA and RS but also for OneRA and pRS. 
Real time RT-PCR was performed in the presence of 0.2x SYBR green I (Molecular 
Probes) using MUR RNA and gene-specific primers (Tables 2.2) (23). RT was performed for 30 
min at 50°C and 15 min at 95°C.  PCR consisted of 50 cycles of 1 min at 60°C, 1 min at 72°C, 7s 
heating to hot-measurement temperature, 13-s hot-measurement at 78°C below product melting 
temperature, and 1 min at 94°C. Hot-measurements were performed to eliminate the detection of 
primer-dimers that tend to have melting temperatures between 72°C and 75°C. PCR was 
followed by melting (60°C to 95°C). Targets were considered present when a single product of 
the appropriate size was obtained. Target sizes were determined by microfluidic electrophoresis 
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(Agilent BioAnalyzer). The average difference between observed and expected product size was 
5.6 ± 3.8 bp (n=25).   
Statistics 
Gene array experiments were performed in triplicate. RT-PCR experiments were 
performed at least in duplicate, mostly in quadruplicate. Data, including quality control values, 
are expressed as average ± SD. The significance of continuous data was determined using One-
way ANOVA with Bonferroni post hoc test. Significance was assumed at p < 0.05.   
Results 
Target yields and amplification 
Samples of total RNA ranging from 0.3 ng to 10 µg were used as starting materials.  
Quantities were verified spectrophotometrically. RNA qualities were evaluated by microfluidic 
electrophoresis (Fig. 2.3). MUR RNA was of slightly higher quality than MK RNA as evident 
from the larger ratio between the 28S and 18S peak. cRNA targets were prepared by OneRA or 
TwoRA starting with 10 µg or 10 ng RNA, respectively. Alternatively, cDNA targets were 
prepared by RS starting with 3, 10, 30 or 100 ng RNA and by pRS starting with 0.3, 3 and 10 ng 
RNA.  Fig. 2.4 summarizes cRNA and cDNA target yields obtained after amplification. Yields 
for cRNA and cDNA targets were significantly different but each was sufficient for preparation 
of the hybridization cocktail (Affymetrix). The size distribution of amplified products and of 
biotinylated and fragmented targets are shown in Fig. 2.5.  
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Figure 2.3: Quality of RNA used as starting material.   
Electropherograms  (BioAnalyzer, Agilent) of (A) mouse kidney (MK) total RNA and (B) mouse 
universal reference (MUR) total RNA. Sharp peaks representing 18S and 28S rRNA demonstrate 
good quality (solid lines), although the mass ratio for the two rRNA species was lower for MK 
RNA. Each sample was spiked with a 25 nt marker to aid alignment of traces with a ladder 
consisting of 200, 500, 1000, 2000 and 4000 nt fragments (shaded traces). 
 
 
 
Figure 2.4: Amplification yields.   
cRNA was obtained from 10 µg total RNA using OneRA and from 10 ng using TwoRA. cDNA 
was obtained from 0.3, 3, 10, 30 or 100 ng total RNA using RS and pRS. Numbers next to error 
bars represent the numbers of experiments conducted.   
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Figure 2.5: Quality of cRNA and cDNA targets obtained after amplification (Amp) and 
fragmentation (Frag).   
(A) Averaged electropherograms of  cRNA targets were prepared using OneRA from 10 µg of 
total RNA (n=3). (B) cRNA targets were prepared using TwoRA from 10 ng of total RNA (n=3). 
(C) cDNA targets were prepared by using RS from 3, 10, 30 or 100 ng of total RNA (n=1 each). 
(D) cDNA targets were prepared using pRS from 10 ng of total RNA (n=2). Each sample was 
spiked with a 25 nt marker to aid alignment of traces with a ladder consisting of 200, 500, 1000, 
2000 and 4000 nt fragments (shaded traces).   
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These target preparation methods, OneRA, TwoRA, RS and pRS, are designed to amplify 
mRNA, priming at the poly-A tail. Adherence to this design goal was evaluated by gene array 
analysis. Poly-A tail independent amplification was evaluated by probes for 18S rRNA, which is 
thought not to contain a poly-A tail and therefore should not be amplified and consequently not 
called present. Probe sets for 18S hybridized with targets prepared by OneRA yielded low signal 
intensities and were not consistently called present (see Fig. 2.6). In contrast, 18S probe sets 
hybridized with targets prepared by TwoRA, RS or pRS were consistently called present. 
Hybridization with targets prepared by TwoRA, RS or pRS yielded high signal intensities. 
   
 
Figure 2.6: Amplification of 18S rRNA.   
Signal intensity of the 3′, M and 5′ probes sets. Probe sets were consistently called present for six 
target preparations prepared using TwoRA or using RS or pRS (each 6/6) but not for targets 
prepared using OneRA.  
Bias toward amplification of the 3′ end of targets was evaluated by probes located toward 
the 3′ and 5′ ends and in the middle of GAPDH, β-actin and transferrin receptor. Signal intensity 
ratios, 3′-5′ and 3′-M, were calculated (Table 2.3). Ratios should ideally be unity. Ratios for 
targets prepared by OneRA were closest to unity. Increase 3′-5′ ratios were noted for all other 
target preparation methods from the lower input total RNA samples. This observation is similar 
to that noted by others and likely does not affect the quality of expression profiling with the 
GeneChip arrays, as the probe design for these arrays is 3′ biased (12). 3′ biases for targets 
prepared by RS and pRS were similar regardless of the amount of starting material. 
 
 43
Table 2.3: Amplification induced 3′ bias, as measured by signal intensity on GeneChip 
arrays.   
Values are averages ± SD. Ratios were obtained for targets that were prepared from MUR RNA 
(each n=3) by one (OneRA), two (TwoRA) rounds of amplification or by Ribo-SPIA™ linear 
amplification (RS and pRS).  OneRA was taken as standard and significantly different data were 
marked with an asterisk. 
Gene Ratio Distances from 3' OneRA (10 µg) TwoRA (10 ng) RS (10 ng) pRS (10 ng) 
GAPDH 3'/M 387 / 770 0.87 ± 0.03 1.09 ± 0.04 * 1.6 ± 0.1 * 1.12 ± 0.02 * 
GAPDH 3'/5' 387 / 1138 0.80 ± 0.03    1.7 ± 0.1* 1.5 ± 0.1 * 1.12 ± 0.03 * 
β-Actin 3'/M 972 / 1298 1.09 ± 0.05    1.2 ± 0.1 2.9 ± 0.2 * 2.5 ± 0.1  * 
β-Actin 3'/5' 972 / 1665 1.17 ± 0.06    1.5 ± 0.1 * 3.1 ± 0.1 * 3.8 ± 0.2  * 
Transferrin 
Receptor 3'/5' 528 / 2225 3.4   ± 0.2 - - - 
The numbers of probe sets that were called present, absent or marginal were tabulated 
(Table 2.4). pRS had the highest number of present calls followed by OneRA, TwoRA and RS, 
respectively. More genes were consistently (in all three replicates) called present after pRS than 
after TwoRA or RS (Fig. 2.7). A sizable number of targets (13,539, based on MUR RNA) was 
amplified by all three methods. Similar observations were made for MK RNA.  For targets 
prepared by RS and pRS, present calls decreased and absent calls increased with decreasing 
amounts of starting material (Table 2.4). Sensitivity was computed as average fold-change 
necessary for significance (Table 2.4). Foldsig was found to be intensity dependent (Fig. 2.8). 
 
Figure 2.7: Venn diagrams of genes consistently called present.   
Target populations were prepared from 10 ng MK or MUR RNA using TwoRA or using RS or 
pRS. 100% is the total of 45,101 probe sets.   
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Table 2.4: Call distribution, call concordance, signal correlation and estimated average 
fold-change necessary for significance.   
Call distributions and call concordances are relative to the total number of 45,101 probe sets. 
Call concordances and signal correlations are based on the three possible comparisons within 
triplicate samples. Estimated average fold-changes necessary for significance (Foldsig) were 
based on average intensity and standard deviation for present genes. Targets were prepared 
from mouse kidney (MK) or mouse universal reference (MUR) RNA using OneRA or TwoRA or 
Ribo-SPIA linear amplification (RS or pRS). Targets prepared using OneRA from 10 µg RNA 
were taken as standard and significantly different data were marked with an asterisk.  
 
Method RNA 
P 
(%) 
A 
(%) 
M 
(%) 
Concordance 
(%) 
Correlation 
(R) 
Foldsig 
OneRA 10 µgMK 42.0 ± 2.1 56.1 ± 2.1 1.94 ± 0.06 90.8 ± 0.6 0.991 ± 0.005 1.27 ± 0.20 
TwoRA 10 ngMK 44.5 ± 1.3 53.5 ± 1.2 1.96 ± 0.06 91.4 ± 0.4 0.99562 ± 0.00004 1.26 ± 0.19* 
        
RS 100 ngMK 45.8 ± 0.5 * 52.4 ± 0.5 * 1.81 ± 0.11 89.7 ± 0.3 * 0.991 ± 0.001 1.33 ± 0.22* 
RS 30 ngMK 45.2 ± 0.7 * 53.0 ± 0.7 * 1.75 ± 0.02 90.0 ± 0.3 0.995 ± 0.001 1.29 ± 0.21* 
RS 10 ngMK 41.7 ± 1.0 56.5 ± 1.0 1.78 ± 0.05 88.4 ± 0.6 * 0.981 ± 0.010  1.44 ± 0.28* 
RS 3 ngMK 41.2 ± 0.2 57.1 ± 0.3 1.77 ± 0.14 88.5 ± 0.2 * 0.990 ± 0.001  1.43 ± 0.30* 
        
pRS 10 ngMK 50.4 ± 0.7 48.2 ± 0.7 1.37 ± 0.06 88.4 ± 0.04 * 0.9957 ± 0.0002 1.39 ± 0.34* 
        
OneRA 10 µgMUR 48.8 ± 0.6 49.3 ± 0.6 1.87 ± 0.03 92.2 ± 0.1 0.9978 ± 0.0002 1.20 ± 0.17 
TwoRA 10 ngMUR 48.8 ± 0.5 49.2 ± 0.5 1.97 ± 0.04 91.8 ± 0.2  0.9964 ± 0.0003  1.24 ± 0.18* 
RS 10 ngMUR 44.2 ± 0.7 * 53.8 ± 0.7 * 1.91 ± 0.06 89.3 ± 0.3 * 0.995 ± 0.001 1.29 ± 0.21* 
        
pRS 10 ngMUR 54.8 ± 1.1 43.7 ± 1.0 1.43 ± 0.12 88.1 ± 0.1 * 0.991 ± 0.005 1.40 ± 0.30* 
pRS 3 ngMUR 53.2 ± 0.9 45.3 ± 0.9 1.43 ± 0.12 87.0 ± 0.3 * 0.990 ± 0.003  1.50 ± 0.39* 
pRS 0.3 ngMUR 45.9 ± 1.2 52.9 ± 1.2 1.27 ± 0.06 83.6 ± 0.8 * 0.966 ± 0.005 * 1.91 ± 0.64* 
Verification of amplification 
A sizable number of targets (13,995 = 13,539 + 456, based on MUR RNA) were 
amplified from 10 ng RNA by both TwoRA and RS (Fig. 2.7). An additional 5,929 (= 2,546 + 
3,383) targets were TwoRA-specific since they were amplified by TwoRA and not by RS and an 
additional 3,093 (= 845 + 2,248) targets were RS-specific since they were amplified by RS and 
not by TwoRA. TwoRA- and RS-specific targets had similar distributions of hybridization 
intensities and of fold-differences between hybridization intensities that were called present and 
called absent. TwoRA- and RS-specific target populations were sampled according to a set of 
criteria (see Methods) that ensured fair comparison between these two systems. All 13 TwoRA-
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specific and all 13 RS-specific targets could be verified in MUR RNA (Tables 2.1) consistent 
with equal fidelity of TwoRA and RS. Of the 26 selected targets 15 were called present by 
OneRA and 24 were called present by pRS. Quantitative comparisons other than between 
TwoRA and RS are not warranted given that unbiased selection was ensured only for TwoRA 
and RS. Taken together, these data demonstrate equal fidelity of TwoRA and RS and suggest 
that each amplification system amplifies a unique set of targets, in addition to the overlapping 
target sets. 
 
 
Figure 2.8: Intensity dependence of estimated fold-change necessary for significance.   
Fold-changes for significance were computed on the basis of averages and standard deviations.  
Traces represent smoothed averages.  A, C, E: Estimated fold-changes for significance 
computed from target populations amplified from different amounts of MK RNA or MUR RNA. 
B, D, F: Smoothed frequency distributions of intensities are provided for comparison. Target 
populations were prepared using OneRA or TwoRA or using RS or pRS.  
Reproducibility between replicates 
Call concordances and correlation coefficients within triplicate samples were calculated 
to evaluate reproducibility between replicates (Table 2.4, best examples are shown in Figs. 9A-D 
and 10). Between replicates call concordances were similar for targets prepared by OneRA or 
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TwoRA and somewhat lower for RS and pRS (92.2%, 91.8%, 89.3% and 88.1%, respectively, 
for target prepared from 10 µg and 10 ng MUR RNA). Signal correlations were similar for 
targets prepared by all amplification systems.  
 
Figure 2.9: Correlation of signal intensities and ratios.   
(A-D) Best examples of correlations of individual data sets (replicates) prepared using OneRA 
or TwoRA or using RS or pRS from MUR RNA. (E-H) Correlation of averaged data sets 
prepared by OneRA, TwoRA, RS or pRS from MK RNA. (I-L) Correlation of ratios computed 
from averaged data sets (MK/MUR) that originated from samples prepared using OneRA, 
TwoRA, RS or pRS. 
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Figure 2.10: Correlation of signal intensity for 0.3 ng total RNA.  
Best example of correlations of individual data sets (replicates) prepared using pRS from mouse 
MUR RNA.  
Fidelity of amplification systems 
Direct comparison 
Call concordances were obtained from comparisons of samples prepared from 10 µg 
RNA by OneRA and from 10 ng by TwoRA, RS or pRS (Table 2.5). Call concordances between 
OneRA and TwoRA were higher than for any other comparison. Observations were similar for 
MK and MUR RNA. Signal intensities were correlated between amplification systems (Fig. 2.9 
E-H). Correlations coefficients were better between OneRA and TwoRA and between RS and 
pRS most likely due to the greater similarities between these amplification systems. Low call 
concordances and signal correlations between T7- and Ribo-SPIA™ -based systems suggests 
that the two amplification methods may introduce different biases or that cDNA and cRNA 
perform differently on GeneChip® arrays. Indeed, cDNA/DNA hybridizations may be more 
reliable than cRNA/DNA hybridization due to the lesser complexity of cDNA/DNA interactions 
(17; 18; 24), which may affect both Present/Absent calls and signal intensities.   
 
 48
Differential gene expression 
Amplification-induced bias in signal intensity can be canceled by computing differential 
gene expression. Signal intensity ratios of data originating from MK and MUR RNA were 
calculated from averages of triplicates. Ratios of samples that were prepared by different 
amplification systems were compared. Correlations coefficients were obtained for probes that 
were called present in all sets of triplicates prepared by OneRA, TwoRA, RS and pRS (Fig. 2.9 
I-L). Correlation between TwoRA and OneRA was considerably better than between other 
amplification systems.  
 
Table 2.5: Call concordances and signal intensity correlations between systems.   
Call concordances are calculated between target populations generated from 10 µg RNA using 
one (OneRA) or from 10 ng RNA by two (TwoRA) rounds of amplification or Ribo-SPIA linear 
amplification (RS or pRS). Call concordances are averages ± SD of the nine possible 
comparisons between two sets of  triplicates. Signal correlation coefficients were obtained from 
correlation of averaged triplicates.   
MK RNA RNA 
Concordance 
(%) 
P–P 
(%) 
A–A 
(%) 
A–P 
(%) 
P–A 
(%) 
Correlation 
(R) 
OneRA – TwoRA K 86.7 ± 0.8 37.6 ± 1.3 49.0 ± 0.9 5.9 ± 1.3 3.7 ± 0.6 0.923 
OneRA – RS K 76.5 ± 1.0 31.2 ± 1.0 45.3 ± 1.1 9.8 ± 1.1 10.1 ± 0.9 0.693 
OneRA – pRS K 60.7 ± 0.3 27.4 ± 1.0 33.2 ± 0.9 22.0 ± 1.1 14.1 ± 0.8 0.702 
TwoRA – RS K 77.5 ± 0.4 32.9 ± 0.6 44.5 ± 0.8 8.1 ± 0.7 10.8 ± 0.6 0.729 
TwoRA – pRS K 60.6 ± 0.2 28.6 ± 0.7 31.9 ± 0.6 20.8 ± 0.7 15.3 ± 0.6 0.730 
RS – pRS K 60.0 ± 0.3 26.9 ± 0.5 33.1 ± 0.7 22.6 ± 0.5 14.3 ± 0.6 0.923 
        
MUR RNA RNA 
Concordance 
(%) 
P–P 
(%) 
A–A 
(%) 
A–P 
(%) 
P–A 
(%) 
Correlation 
(R) 
OneRA – TwoRA UR 87.6 ± 0.2 43.5 ± 0.3 43.9 ± 0.4 4.4 ± 0.3 4.5 ± 0.3 0.930 
OneRA – RS UR 74.0 ± 0.3 34.6 ± 0.4 39.3 ± 0.4 8.9 ± 0.3 13.4 ± 0.5 0.685 
OneRA – pRS UR 59.3 ± 0.1 32.6 ± 0.3 26.7 ± 0.2 21.8 ± 0.3 15.6 ± 0.3 0.734 
TwoRA – RS UR 75.3 ± 0.3 35.3 ± 0.5 40.0 ± 0.3 8.3 ± 0.3 12.7 ± 0.5 0.701 
TwoRA – pRS UR 58.7 ± 0.2 32.3 ± 0.3 26.4 ± 0.2 22.0 ± 0.2 15.9 ± 0.2 0.741 
RS – pRS UR 56.6 ± 0.2 28.9 ± 0.4 27.6 ± 0.3 25.4 ± 0.4 14.8 ± 0.2 0.907 
Discussion 
Microarray-based gene expression profiling of microdissected tissue samples and needle 
biopsies is often limited due to insufficient amounts of RNA. Methods devised to overcome this 
limitation include signal amplification (8; 20) and sample amplification including exponential 
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amplification by PCR (7; 9; 13; 16; 22) and linear amplification by T7 polymerase (1; 4; 15; 21).  
T7-based linear amplification methods including TwoRA are commonly used for preparation of 
targets from nanogram amounts of RNA (3; 21). RS and pRS are novel systems that are based on 
Ribo-SPIA™ technology that was recently introduced as an alternative to TwoRA. The goal of 
the present study was to compare RS, pRS, TwoRA and OneRA. Target yields and qualities, 
amplification biases, call concordances, correlation coefficients and sensitivities were 
determined. Evaluations were based on direct comparisons and on differential gene expression.  
OneRA was taken as baseline, mostly for historical reasons (11). Although, OneRA is the major 
linear amplification protocol used on the Affymetrix platform, it should not be assumed to 
generate a ‘true’ or ‘standard’ gene expression profile as implied by its commercial name. 
RS and pRS generated significantly smaller amounts of cDNA than TwoRA generated 
cRNA (Fig. 2.4), although all systems produced sufficient amounts of targets given that 15 µg of 
cRNA and only 2 µg of cDNA are needed for array hybridization. Yields of cDNA targets 
prepared by RS and pRS were independent of the amount of starting material, which is similar to 
the pattern observed with PCR. 
Probe sets for 18S rRNA were low in signal intensity and inconsistently called present in 
targets prepared by OneRA. However, 18S rRNA was consistently called present with high 
signal intensities in target preparations prepared by TwoRA, RS and pRS (Fig. 2.6). This 
observation may indicate that both T7- and Ribo-SPIA™- based amplification systems prime at 
internal poly-A sites. Alternatively, it is conceivable that poly-adenylated forms 18S rRNA may 
be present as has recently been observed in yeast (10). Thus, it is possible that the higher 
sensitivity afforded by RNA amplification enables the detection of small amounts of poly-
adenylated rRNA on the arrays. The majority of amplified transcripts generated by RS and pRS 
were up to 1,000 nt in length (Fig. 2.5). A similar length distribution was found for TwoRA. In 
contrast, the majority of amplified transcripts generated by OneRA were up to 2,500 nt in length. 
These differences are not likely to be important on Affymetrix arrays in which >98% of the 
probe sets are located less than 600 nt from the 3′ end.  
3′ bias was further determined for three genes with probe sets that varied in their 
distances from the 3′ end of the mRNA (Table 2.3). 3′/M and 3'/5' ratios for GAPDH are best 
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suited to predict fidelity of expression profiling given that >98% of probe sets on Affymetrix 
mouse 430 2 chips are specific for sequences within 600 nt from the 3′ end. The observation that 
3′/M and 3'/5' ratios for GAPDH were close to unity is consistent with the view that TwoRA, RS 
and pRS amplify targets with high fidelity. The observation that 3'/5' ratios for the transferrin 
receptor, which are based on probe sets located 528 and 2,225 nt from the 3' end, could only be 
obtained for OneRA is consistent with the finding that OneRA yielded longer transcripts than 
TwoRA, RS or pRS. 
The RNA starting material for MK and MUR differed notably in quality (Fig. 2.3).  
Consistently, significant differences between MK and MUR RNA were found for probe sets that 
are located 972 and 1665 nt from the 3′ end (3′-5′ ratio for β-actin, Fig. 2.11). However, no 
significant differences were found for ratios of probes set that are located 387 and 770 nt from 
the 3′ end (3′/M ratio for GAPDH, Fig. 2.11). Given that >98% of probes are located within 600 
nt of the 3′ end, the difference in RNA quality was not expected to have a major effect on the 
gene array data. Consistently, analyses of GeneChip array data from both RNA gave similar 
results. 
A sizable number of targets (13,539 in 10 ng MUR RNA) were detected by TwoRA, RS 
and pRS. The highest number of genes (21,652 in 10 ng MUR RNA) was consistently called 
present in targets prepared by pRS compared to RS and TwoRA (Fig. 2.7). pRS consistently 
amplified 15,179 targets from 0.3 ng of total RNA with acceptable reproducibility as measured 
by call concordance, signal correlation and sensitivity (Table 2.4, Fig. 2.8 and 2.10). Verification 
of 13 TwoRA- and 13 RS-specific targets by RT-PCR (Table 2.2) demonstrate that TwoRA and 
RS amplify partially unique sets of targets. 
Reproducibility between replicates was based on call concordance and estimated fold-
changes necessary for significance (Table 2.4, Fig. 2.8). Reproducibility for targets that were 
prepared from 10 ng RNA by TwoRA was higher than for targets that were prepared from 10 ng 
RNA by RS or pRS.  Fold-changes necessary for significance, however, were well below 2 for 
all amplification systems. A fold change of 2 is sometimes used as an arbitrary lower limit for 
significance.   
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Figure 2.11: 3′ bias as a function of the quality of the RNA starting material. 
 MK RNA was of slightly lesser quality than MUR RNA as evident from the lesser ratio of the 
18S and the 28S peaks, (see Fig. 3). Targets were prepared using OneRA from 10 µg RNA, 
TwoRA from 10 ng RNA or RS or pRS from 10 ng RNA. A-D: 3′/M and 3′/5′ ratios for GAPDH 
and β-actin, n=3 for each ratio. *Significant differences between MK and MUR RNA. Note that 
no significant differences are found for OneRA and for ratios that span short distances. 
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As expected, comparisons of targets populations prepared by different amplification 
methods yielded poorer call concordances and signal intensity correlations than comparisons of 
targets populations prepared by the same method (9; 14). This difference illustrates the presence 
of system-specific biases. 
Call concordances were higher between the two T7-based systems, OneRA and TwoRA, 
than between T7- and Ribo-SPIA™-based systems (Table 2.5), most likely due to the greater 
similarity of the methods and the similar number of present calls. Although RS and pRS are 
similar methods, they differed greatly in the number of present calls, which resulted in a poorer 
call concordance. Signal correlation coefficients within the two T7-based (OneRA and TwoRA) 
or within the two Ribo-SPIA™-based methods (RS and pRS) were significantly higher than any 
comparison between these methods (Table 2.5, Fig. 2.9 E-H). The observation that A-P calls 
between OneRA and TwoRA or between OneRA and pRS were significantly larger than P-A 
calls is consistent with amplification of rare messages by TwoRA and pRS. Amplification is 
likely to raise signal intensities of rare genes above the noise level (6).   
Differential gene expression was computed in an attempt to cancel system-dependent 
biases. Nevertheless, correlation between ratios of targets prepared by T7-based systems, 
TwoRA and OneRA, was considerably better than between ratios of T7- and Ribo-SPIA™-based 
methods (Fig. 2.9 G-I). This observation underscores the presence of system specific biases.   
All nanogram amplification methods, TwoRA, RS and pRS, yielded sufficient material 
for gene array work, although TwoRA yielded quantitatively more cRNA than RS or pRS 
yielded cDNA. The RS and pRS target preparation methods produced results comparable to 
those observed using more traditional T7-based methods and will enable studies of smaller RNA 
samples because the required input level is lower and the time and effort required for 
amplification are lower. pRS reproducibly amplified the highest number of targets and was found 
to be suitable for amplification of total RNA from amounts as low as 0.3 ng. Reproducibility and 
sensitivity of TwoRA, relative to OneRA, were higher than those of RS or pRS. All 
amplification systems, OneRA, TwoRA, RS and pRS, amplified large overlapping sets of 
targets. Target preparations using RS and pRS were faster and produced cDNA, which is more 
stable than cRNA and thus can be banked for additional studies. The presence of system-specific 
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biases prompts the recommendation that changes in amplification methodology within a study be 
avoided. Indeed, in the anticipation of future refined studies on nanogram amounts RNA, 
investigators may want to choose a nanogram amplification system for a pilot study even if 
microgram amounts of RNA are available.   
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CHAPTER 3 - Free radical stress-mediated loss of Kcnj10 protein 
expression in stria vascularis contributes to deafness in Pendred 
syndrome mouse model 
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Abstract 
Pendred syndrome is due to loss-of-function mutations of Slc26a4, which codes for the 
HCO3- transporter pendrin. Loss of pendrin function causes deafness via a loss of the K+ channel 
Kcnj10 in stria vascularis and consequent loss of the endocochlear potential. Pendrin and Kcnj10 
are expressed in different cell types. Here we report that free radical stress provides a link 
between the loss of Kcnj10 and the loss of pendrin. Studies were performed using native and 
cultured stria vascularis from Slc26a4+/- and Slc26a4-/- mice as well as CHO-K1 cells. Kcnj10, 
oxidized proteins and proteins involved in iron metabolism were quantified by Western blotting.  
Nitrated proteins were quantified by ELISA. Total iron was measured by ferrozine 
spectrophotometry and gene expression was quantified by qRT-PCR. At postnatal day 10 ( P10), 
stria vascularis from Slc26a4+/- and Slc26a4-/- mice expressed similar amounts of Kcnj10. 
Slc26a4-/- mice lost Kcnj10 expression during the next 5 days of development. In contrast, stria 
vascularis, obtained from P10 Slc26a4-/- mice and kept in culture for 5 days, maintained Kcnj10 
expression. Stria vascularis from Slc26a4-/- mice was found to suffer from free radical stress 
evident by elevated amounts of oxidized and nitrated proteins and other changes in protein and 
gene expression. Free radical stress induced by 3-morpholinosydnonimine-N-ethylcarbamide 
(SIN-1) was found to be sufficient to reduce Kcnj10 expression in CHO-K1 cells. These data 
demonstrate that free radical stress provides a link between loss of pendrin and loss of Kcnj10 in 
Slc26a4-/- mice and possibly in human patients suffering from Pendred syndrome. 
Keywords 
Cochlea; pendrin; oxidation; nitration 
Introduction 
Pendred syndrome, the most frequent hereditary form of syndromic deafness, is an 
autosomal recessive disease that affects the inner ear and the thyroid and causes childhood 
deafness and post puberty goiter (9; 21; 29). It is caused by loss-of-function mutations of the 
gene SLC26A4, which encodes the anion exchanger pendrin (13; 16; 32). Pendrin has been 
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characterized in heterologous expression systems to be an anion exchanger that accepts Cl-, 
HCO3-, I-, and formate (37).   
Investigations of the cause of deafness in Pendred syndrome have recently been 
facilitated by the creation of mouse model (12). The following observations have been made in 
the Pendred syndrome mouse model: 1) Enlargement of endolymphatic spaces prenatally. 2) 
Acidification of endolymph at P10. 3) Increased Ca2+ concentration in the endolymph at P10. 4) 
Reduction in endocochlear potential at P10. 5) Loss of Kcnj10 protein expression at P15; 6) 
Macrophage invasion in stria vascularis at ~P35. 7) No changes in endolymphatic K+ 
concentration in adult mice. 8) Degeneration of strial marginal cells in adult mice (12; 20; 42; 
44). 
In the cochlea, pendrin is mainly expressed in the apical membrane of outer sulcus and 
spiral prominence epithelial cells that border endolymph (Fig. 3.1) (14; 42). The observation that 
loss of pendrin leads to acidification of endolymph suggests that pendrin mediates HCO3- 
secretion (28; 44).   
Sensory transduction in the cochlea depends on the endocochlear potential, which is 
generated by the K+ channel Kcnj10 in stria vascularis (26; 41). The generation of a small 
endocochlear potential at P10 is consistent with the expression of K+ channel Kcnj10. Both 
Kcnj10 expression and endocochlear potential are lost during further development and 
consequently Slc26a4-/- mice never develop hearing (42; 44). 
Loss of pendrin cannot directly affect Kcnj10 protein expression, since Kcnj10 and 
pendrin are expressed in different cells in the cochlear lateral wall (Fig. 3.1A) (42; 44). In this 
study we hypothesize that free radical stress could be the link between loss of pendrin and 
reduction of Kcnj10 protein expression.   
Increased oxidative stress in the Pendred Syndrome mouse model may be a consequence 
of enlarged endolymphatic spaces and/or the acidic endolymph. The K+ concentration  is 
maintained at normal levels in the enlarged Slc26a4-/- endolymph volume, which implies 
increased rates of  K+ secretion by stria vascularis to compensate for K+ leakage  (42). The rate 
of ion transport correlates with ATP production and metabolism in stria vascularis (23; 25).  
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Elevated rates of K+ secretion in the stria vascularis of Slc26a4-/- mice could enhance free radical 
stress as a result of increased energy metabolism, which is a major source of oxygen free 
radicals. Oxidative stress in stria vascularis may also be a consequence of endolymph 
acidification. The acidic pH of endolymph could reduce the cytosolic pH in strial marginal cells 
that border endolymph. Cytosolic acidification is a condition favorable to release of iron from 
proteins and in the presence of superoxide anion (O2•-), nitric oxide radical (•NO) leads to the 
formation of peroxynitrite (ONOO-) and hydroxyl radical (•OH-) (4; 10).   
 
Figure 3.1: Schematic diagram for Kcnj10 and pendrin expression in the cochlea.   
(A) Kcnj10 is expressed in intermediate cells (blue) inside stria vascularis and pendrin is mainly 
expressed in spiral prominence epithelial cells, root cells and in outer sulcus epithelial cells 
(green). (B) Two preparations were obtained from the lateral wall of the cochlea. The 
preparation of stria vascularis contained the K+ channel Kcnj10 and the preparation of spiral 
ligament contained pendrin in cells located in spiral prominence epithelial cells, root cells and 
in outer sulcus epithelial cells.  Both Kcnj10 and pendrin are lost in Slc26a4-/- mice. The 
preparation of spiral ligament also contained remnants of Reissner’s membrane in addition to 
the spiral ligament.   
Oxygen free radicals can originate from a leaky electron transfer in the mitochondrial 
electron transport chain during production of ATP. Incomplete reduction of O2 during 
metabolism generates the free radical (O2•-), which spontaneously dismutates to hydrogen 
peroxide (H2O2). These two reactive oxygen species can be involved in further reactions that 
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generate more aggressive, damaging radicals. In the presence of Fe2+, H2O2 can enter into the 
Fenton reaction that yields the extremely aggressive •OH-. •NO  synthesized by nitric oxide 
synthase can react with •O2- to yield peroxynitrite (ONOO-) which decomposes to form •OH- and 
nitrate radical (•NO2) (5; 40). Transition metal ions bound to lipids and proteins can react with 
H2O2, •OH-  and •NO2 to generate intermediates that subsequently cause oxidation and nitration 
of proteins and lipids, impairing the ability of the cell to function normally (30; 38).   
Defense mechanisms against free radical stress entail sequestration of catalysts that 
promote the formation of free radicals and detoxification by chemical conversion. The free 
radical •O2- can be converted to O2 and H2O by superoxide dismutase in conjunction with 
catalase or glutathione peroxidase. Catalysts that generate free radicals, such as Fe, Zn and Cu, 
are sequestered by ferritin, metallothionein, and ceruloplasmin (34; 36; 46). The cellular 
availability of the catalyst Fe is controlled via transcriptional and translational mechanisms. The 
expression of the Fe chelator transferrin (Trf ) and the uptake mechanism transferrin receptor 
(Tfrc) are controlled by an iron-response protein, aconitase (Aco1) (8; 11). When the cytosolic 
free Fe concentration is high, retardation of Tfrc mRNA degradation is lifted and translation of 
Trf is promoted leading to an increased expression of the chelator Trf and a decreased expression 
of the Fe uptake mechanism Tfrc. Together, these changes in the expression of Fe related 
proteins can mediate a reduction in the cytosolic free Fe concentration. Decreases in Tfrc 
transcript and increases in Trf protein expression, however, are often not sufficient to control 
oxidative stress and can be taken as an indication for the presence of Fe-mediated oxidative 
stress.   
In the present study, we obtained direct and indirect measures of oxidative and nitrative 
stress before and after the onset of hearing in stria vascularis and a preparation of spiral ligament 
that included pendrin-expressing outer sulcus and spiral prominence epithelial cells. The levels 
of oxidized and nitrated proteins in conjunction with the mRNA expression of genes involved in 
antioxidant defenses were used to assess oxidative and nitrative stress. We evaluated the impact 
of oxidative and nitrative stress on the protein levels of Kcnj10 using an expression system 
model. To ascertain whether the loss of Kcnj10 was a consequence of the conditions prevalent in 
the stria vascularis of Slc26a4-/-mice, stria vascularis from P10 organ cultures and the 
corresponding time points in vivo were compared for the protein level expression of Kcnj10.  
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Methods 
Animal use and tissue preparations 
The Slc26a4-/- mouse strain was created in the laboratory of Dr.Eric Green at the National 
Institute of Health (12). Slc26a4-/- and Slc26a4+/- mice were raised in a colony at Kansas State 
University that was established with breeders kindly provided by Dr. Susan Wall (Emory 
University).  Mice were deeply anesthetized with tribromoethanol (560 mg/kg, i.p.) and 
sacrificed by transcardial perfusion with Cl- free solution. Cl- free solution contained (in mM) 
150 Na-gluconate, 1.6 K2HPO4, 0.4 KH2PO4, 4 Ca2+-gluconate, 1 MgSO4 and 5 glucose, pH 7.4.  
Temporal bones housing the cochleae were removed and separate fractions of stria vascularis 
and spiral ligament were obtained by microdissection (Fig. 3.1B). All procedures concerning 
animals were approved by the Institutional Animal Care and Use Committee of Kansas State 
University. 
Quantitative RT-PCR 
Real time RT-PCR in presence of SYBR green (Molecular Probes, Eugene, OR) was 
carried out in 96-well plates (OneStep RT-PCR Kit, Qiagen Valencia, CA; iCycler, BioRad, 
Hercules,CA) using gene specific primers (Table 3.1). Transcripts were quantified in paired 
experiments using one master mix and total RNA isolated from pairs of age and sex matched 
Slc26a4-/- and Slc26a4+/- mice. RT was performed for 30 min at 50°C and terminated by heating 
to 95°C for 15 min.  PCR consisted of 40 cycles of 1 min annealing at 60°C, 1 min elongation at 
72°C, 20s hot-measurement at 78°C, and 1 min denaturation at 94°C. Amplification of a single 
product was verified by gel electrophoresis and identity of the product was verified once by 
sequencing. The number of template molecules (T) was calculated according to T = 10^ log 
(number of molecules at Ct) / (PCR efficiency^Ct). Ct was defined as the cycle at which the 
fluorescence of the product molecules reached a set threshold. The number of molecules at Ct 
was calibrated by amplifying known numbers of 18S rRNA molecules. The content of 18S in 
total RNA was estimated under the assumption that total RNA consists of 100% of 18S and 28S 
rRNA. PCR efficiency was obtained from the slope of the log-linear phase of the growth curve 
(31). 
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Table 3.1: Gene specific primers 
Gene Primers Product size 
Superoxide dismutase (Sod2)  aca agc aca gcc tcc cag a (sense) 
tag cct cca gca act ctc ct (antisense) 291 bp 
Metallothionein 3 (Mt3) gga tat gga ccc tga gac (sense) 
gac acc cag cac tat tta c (antisense) 260 bp 
Aconitase  (Aco1)  cag gat gga tgc tac tac c (sense) 
gga ggt gct tgg taa tgg (antisense) 232 bp 
Transferrin (Trf) act gct ctg cct tga caa tac (sense) 
cac gcc ttc ctg ctg att c (antisense) 319 bp 
Transferrin receptor (Trfr)  ttc cgc cat ctc agt cat cag (sense) 
tgg act tcg ccg caa cac (antisense) 300 bp 
Ferritin (Ftl1)  agc gtc tcc tcg agt ttc ag (sense) 
agg ttg gtc aga tgg ttg c (antisense) 200 bp 
Isolation of protein 
Tissue fractions were transferred from the dissection dish into 0.5 ml microcentrifuge 
tubes and Cl- free solution was removed after a pulse spin.  Four different methods for protein 
isolation were used. Method 1: Proteins were extracted by first adding 20 µl protein extraction 
buffer 1 (ReadyPrep Sequential Extraction Kit, Cat# 163-2101 and 163-2102, BioRad) and 
vortexing for 3 min. The homogenized tissue was centrifuged at 16,000 rpm for 10 min at RT. 
Subsequently extraction buffer 2 was added and the process was repeated. Proteins in the 
supernatant were transferred into a new tube and either used immediately or stored at -80°C. 
Method 2: Proteins were extracted by adding 30 µl of Tris-Triton buffer (50 mM Tris, 150 mM 
NaCl, 1% Triton-X) and incubating for 30 min in a sonicating water bath at 0°C (Fisher 
Scientific FS20). Proteins in the supernatant were transferred to a new tube and either used 
immediately or stored at -80°C. Method 3: Proteins were extracted by adding 30 µl of Tris-SDS 
buffer (50 mM Tris, 150 mM NaCl, 0.5% SDS) and incubating for 30 min in a sonicating water 
bath at 0°C. Proteins in the supernatant were transferred to a new tube and either used 
immediately or stored at -80°C.  Method 4: The tissue was fixed in 0.6 N trichloroacetic acid on 
ice, centrifuged at 15,000 rpm for 10 min at 4°C and the supernatant was removed. The proteins 
were extracted by adding 30 µl of Urea buffer (9 M Urea, 0.065 mM DTT, 2% Triton-X) and 
incubating for 30 min in a sonicating water bath at 0°C. The protein containing solution was 
neutralized by adding 1 M Tris. To this solution 5 µl of 1% SDS was added and resulting 
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mixture was incubated for 30 min in a sonicating water bath at 0°C. Proteins in the supernatant 
were transferred to a new tube and either used immediately or stored at -80°C. 
Detection of oxidized proteins 
Carbonyl groups of oxidized proteins were derivatized with dinitrophenylhydrazine 
(Oxyblot Kit, Cat# S7150, Millipore, Billerica) to form denitrophenylhydrazone (DNP). DNP-
labeled proteins were separated by SDS gel electrophoresis (5µl/lane) and detected in Western 
blots. Procedures were carried out according to manufacturer’s recommendations. Differences in 
the presence of oxidized proteins were evaluated by comparison to the expression of actin or 
tubulin. 
Quantitation of nitrotyrosine by ELISA  
Protein was isolated using the Tris-Triton method (method 2) and the level of 
nitrotyrosine was quantified by two different immunoabsorbent assays (Cat# HK501, Cell 
sciences, Canton, MA; Cat#17-376, Millipore) according to manufacturer’s recommendation. 
The total protein content of the sample was measured. (NanoOrange protein quantitation kit, Cat 
# N666, Invitrogen, Carlsbad, CA). Differences in the amount of nitrotyrosine was evaluated by 
comparison of nitrated protein content to the total protein content. 
Quantitative western blotting 
An equal volume of Laemelli buffer containing 5% β-mercaptoethanol was added to the 
protein samples and incubated at 75°C for 10 min. Protein samples (15 µl) were separated by 
SDS-PAGE gel electrophoresis (4-15% Tris-SDS Polyacrylamide Precast Gels, BioRad). After 
separation, proteins were transferred to either nitrocellulose or PVDF membranes (0.2 µm pore 
size, BioRad), blocked with 5% dry milk in TBS-Tween (137 mM NaCl, 20 mM Tris-Cl, 0.1% 
Tween-20, pH 7.6) and probed with primary antibodies (rabbit anti-Kcnj10, 1:1000, Cat# APC-
035, Alomone labs, Jerusalam, Israel; mouse anti-Kcnj10, Cat# H00003766-M01, Novus 
Biologicals, Littleton, CO; rabbit anti-trf, 1:750, Cat #A76, Biomeda, Foster City, CA; mouse 
anti-tfrc 1:2,000, Cat #13-6800, Zymed, San Francisco, CA; rabbit anti-actin, 1:1000, Cat# 
A2066, Sigma, St. Louis, MO; rabbit anti-tubulin, 1:500, Cat# ab6046, Cambridge, MA).  
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Membranes were washed 4x for 15 min in TBS-Tween and incubated with HRP-conjugated 
secondary antibodies (anti-rabbit, 1:100,000, Cat# 1858415; anti-mouse, 1:100,000, Cat# 
1858416, Pierce, Rockford, IL). After washing, 4x for 15 min in TBS-Tween, HRP was detected 
by chemiluminescence (SuperSignal West Femto Maximum Sensitivity Substrate, Cat# 34095, 
Pierce) using a camera based imaging workstation (4000MM, Kodak). Quantification of 
oxidized proteins and of Kcnj10 protein was carried out by integration of signals arising from 
specific staining (Fig. 3.2). Differences in Kcnj10 expression was evaluated by comparison to the 
expression of actin or tubulin. 
 
Figure 3.2: Illustration of the method used for the quantification of oxidized proteins and 
of Kcnj10 protein expression.   
Chemiluminescence was detected a digital format using a camera-based system (Kodak 4000 
MM).  Staining, consisting of both smears and bands, was observed for oxidized proteins as well 
as for Kcnj10 protein. The specificity of smears and bands was confirmed in independent 
experiments. The intensity of staining was integrated over the entire length of the blot.   
Immunoprecipitation 
Protein was isolated using the Tris-Triton method (method 2).  An equal volume of 
sepharose protein G beads (Cat#P3296, Sigma) was added to protein lysate followed by 
incubation on ice for 60 min. This mixture was spun at 10000 x g for 10 min at 4°C and the 
supernatant (precleared lysate) was transferred to a fresh microcentrifuge tube. 10 µg of mouse 
monoclonal antibody for Kcnj10 was added to the cold precleared lysate and the mixture was 
incubated at 4°C for 1 hr.  50 µl of protein G beads washed in Tris-Triton buffer was added to 
the antibody-lysate mixture followed by incubation for 3 hr at 4°C on a shaker. The supernatant 
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was removed after a quick spin (10000 x g for 30 sec) and the beads were washed 4x in Tris-
Triton buffer. 50 µl of 1x Laemelli buffer was added to the bead pellet and this mixture was 
vortexed and heated at 95°C for 15 min followed by centrifugation at 10000 x g for 5 min. The 
supernatant was collected in a fresh microcentrifuge tube and used as the sample for Western 
blotting. 
Quantification of total tissue Fe content 
Total tissue Fe content (tissue-Fe) was measured using a modified ferrozine-based assay 
(15). Freshly isolated tissue fractions of stria vascularis and spiral ligament were transferred into 
microcentrifuge tubes and Cl--free solution was removed. Guanidine hydrochloride (2 µl) was 
added to the tissue and mixing was facilitated by a pulse spin. After incubation for 45 min at 
60°C, 2 µl of FAT solution was added. FAT solution contained 0.5 M ferrozine, 0.5 M ascorbic 
acid and 1 M Tris-Cl, pH 7. Mixing was facilitated by a pulse spin and the tissue was incubated 
for 45 min at 60°C. Absorbance at 562 nm was measured in the supernatant of the 4 µl sample 
(ND1000, Nanodrop Technologies) and standards containing FeCl2 that were processed in 
parallel.  Following Tissue-Fe measurements, the total protein content of samples was 
determined (NanoOrange Protein Quantitation Kit). Measurements of the Tissue-Fe are reported 
per mg protein. 
Organ culture 
Freshly microdissected stria vascularis from P10 Slc26a4-/- and Slc26a4+/- mice was 
cultured in 35 mm flat bottom culture dishes (Cat# 08-757-100A, Fisher) containing 2 ml media 
for 1, 3 and 5 days.  The media consisted of DMEM (Cat# 30-2002, ATCC) supplemented with 
10 % fetal bovine serum (FBS, Cat# 30-2020, ATCC)FBS, 500 µM furosemide (Cat# F4381, 
Sigma-Aldrich)  in) and 1% pencillin-streptomycin antibiotic mixture. The media was changed 
every day. Cultured stria vascularis at the end of 1, 3 and 5 days was transferred from the culture 
dish to a 0.5 ml microcentrifuge tube and washed twice with Cl- free solution to remove excess 
media.  Protein was isolated using the Tris-Triton buffer (method 3). Protein was either used 
immediately or stored at -80°C. 
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Cell culture 
Chinese hamster ovary cells, CHO-K1  (Cat# CRL-9618, ATCC, Manassas, VA) were 
cultured as monolayers in Dulbecco’s minimal essential medium (DMEM) supplemented with 
10% FBS and 1% pencillin-streptomycin antibiotic mixture (Cat# 30-2300, ATCC) in a cell 
culture incubator maintained at 37°C and 5% CO2. The CHO-K1 cells were transfected in a T25 
flask (Cat # 10-126-39, Fisher, St. Louis, MO ) with a GFP-Kcnj10-Export sequence plasmid (a 
generous gift from Dr. Nikolaj Klocker, Dept of Physiology, University of Freiburg, Germany) 
using Lipofectamine 2000TM (Cat# 11668-019, Invitrogen) according to manufacture’s 
instructions. The CHO-K1 cells containing the GFP-Kcnj10-Export plasmid were split 24 hrs 
post transfection and seeded in three wells. To replicate the conditions of organ culture, 500 µM 
furosemide was added to each well 48 hours post transfection and wells were subjected to 
different levels of oxidative and nitrative stress. The first of the three wells was exposed to 
oxidative stress by adding 10 µM H2O2 (Cat# H1009, Sigma-Aldrich, St. Louis, MO). The 
second well was exposed to oxidative and nitrative stress by adding 1 mM SIN-1 hydrochloride 
(Cat# M5793, Sigma-Aldrich). The third well served as a control. This protocol was devised to 
ensure that differences in transfection efficiency did not impact the results. After twelve hours, 
cells were lysed and protein was extracted using the Tris-Triton buffer. Protein was either used 
immediately or stored at -80°C. 
Statistical Analysis 
Data are expressed as averages ± SE. Data were compared by paired and unpaired t-test 
as appropriate. Significance was assumed at P < 0.05. 
Results 
Stria vascularis contains elevated levels of nitrated proteins 
The amount of nitrated proteins in relationship to the total protein was quantified at ages 
P15 and P35 in stria vascularis and the spiral ligament preparation of Slc26a4-/- and Slc26a4+/- 
mice (Fig. 3.3A). Increased levels of nitration were observed in stria vascularis but not in the 
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spiral ligament preparation of Slc26a4-/- compared to Slc26a4+/- mice. The increased levels of 
nitrated proteins suggest that stria vascularis of Slc26a4-/- mice is under increased nitrative stress. 
 
Figure 3.3: Quantification of nitrated and oxidized proteins.   
(A) Nitrated proteins were quantified against total protein in stria vascularis and in the 
preparation of spiral ligament in Slc26a4+/- and Slc26a4-/- mice at ages P15 and P35. Data are 
presented as percent of nitrated protein in stria vascularis of Slc26a4+/- mice. Significant 
changes are marked (*) and numbers next to the bars represent the number of experiments. (B) 
Oxidized proteins were quantified against actin or tubulin in stria vascularis and in the 
preparation of spiral ligament in Slc26a4+/- and Slc26a4-/- mice at ages P10 and P15. 
Representative examples of three experiments are shown. Increased amounts of nitrated and 
oxidized proteins were found in stria vascularis but not in the preparation of spiral ligament of 
Slc26a4-/- mice. The presence of nitrated and oxidized proteins indicates increased nitrative and 
oxidative stress in stria vascularis. 
Stria vascularis contains elevated levels of oxidized proteins 
The presence of oxidized proteins was evaluated at P10 and P15 in the stria vascularis 
and the spiral ligament preparation of Slc26a4-/- and Slc26a4+/- mice (Fig. 3.3B). Detection of 
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oxidized proteins involved DNP-labeling of carbonyl groups in oxidized proteins by 
derivatization with DNPH.  DNP-labeled proteins were detected by Western blot. No labeling 
was observed in the absence of derivatization. The levels of oxidized proteins were increased in 
stria vascularis but not in the spiral ligament preparation of Slc26a4-/- compared to Slc26a4+/- 
mice. The increased levels of oxidized proteins indicate that stria vascularis of Slc26a4-/- mice is 
under increased oxidative stress.  
Antioxidant defenses are reduced in stria vascularis  
Transcripts coding for superoxide dismutase (Sod2) and metallothionein (Mt3) were 
quantified in stria vascularis and in the spiral ligament preparation of Slc26a4-/- and Slc26a4+/- 
mice (Fig. 3.4). Expression of Sod2 was reduced in stria vascularis of Slc26a4-/- mice at ages P10 
and P30. Further, transcripts for Mt3 were reduced in stria vascularis of Slc26a4-/- mice at P15.  
No changes in expression of Sod2 and Mt3 were found in spiral ligament. These observations 
suggest that defenses against free radical stress are weakened in stria vascularis of Slc26a4-/- 
mice before and after the onset of hearing. 
Altered iron metabolism in stria vascularis is consistent with oxidative stress 
Transcripts were quantified in stria vascularis and in the spiral ligament preparation of 
Slc26a4+/- and Slc26a4-/- mice (Fig. 3.5). Transcripts included the Fe uptake mechanism 
transferrin receptor (Tfrc), the Fe chelator transferrin (Trf), the Fe storage protein ferritin (Ftl1), 
and the expression regulator iron responsive protein (Aco1). Quantifications were performed 
before (P10) and after the onset of hearing (P15), after weaning (P30-P35) and in adulthood 
(P75). The numbers of transcripts coding for Tfrc were found to be reduced in Slc26a4-/- mice 
and this reduction was observed in stria vascularis at all ages including P10, and in the spiral 
ligament preparation at P75. The number of transcripts coding for Trf was elevated in Slc26a4-/- 
mice compared to Slc26a4+/- mice and this elevation was observed in stria vascularis from P35 
onward but not in the spiral ligament preparation. Transcripts for Ftl1 were found reduced in 
number and this reduction was seen in stria vascularis from P15 onward and in the spiral 
ligament preparation at P10 and at P75. In addition, transcripts for Aco1 were present in stria 
vascularis and spiral ligament of Slc26a4+/- and Slc26a4-/- mice. No difference in the number of 
 70
transcripts was seen in stria vascularis of Slc26a4-/- compared to Slc26a4+/- mice, however, 
transcripts in the spiral ligament preparation were reduced at P15 and at P75.  
 
Figure 3.4: Quantification of transcripts coding for free radical defenses.   
(A-B) Transcripts coding for superoxide dismutase (Sod2) and metallothionein (Mt3) were 
quantified relative to 18S in stria vascularis and in the preparation of spiral ligament from 
Slc26a4+/- and Slc26a4-/- mice at age P10, P15 and P30. Significant changes are marked (*) and 
numbers next to the data represent the number of animal pairs. Reductions in the number of 
transcripts, which indicates weakened defenses against free radical stress, were seen in stria 
vascularis but not in spiral ligament. 
Protein expression of Trf and Tfrc was quantified at age P35 in stria vascularis and the 
spiral ligament preparation of Slc26a4+/- and Slc26a4-/- mice (Fig. 3.6). Protein expression of Trf 
was increased and protein expression of Tfrc was decreased in stria vascularis but not in the 
spiral ligament preparation of Slc26a4-/- mice compared to Slc26a4+/- mice. The increase in Trf 
expression is consistent with the increase in Trf transcripts (Fig. 3.5) and with Aco1 mediated 
translational expression regulation via an elevated free Fe pool. The decrease in Tfrc expression 
is consistent with the observed decrease in transcripts and Aco1 mediated transcriptional 
regulation via an elevated free Fe pool.  
 71
 
Figure 3.5: Quantification of transcripts coding for proteins involved in Fe metabolism. 
Transcripts coding for transferrin receptor (Tfrc), transferrin (Trf), ferritin (Ftl1) and Fe 
responsive protein (Aco1) were quantified relative to 18S in stria vascularis (left-side graphs) 
and in the preparation of spiral ligament (right-side graphs) of Slc26a4+/- and Slc26a4-/- mice at 
different ages. Significant changes are marked (*) and numbers next to the data represent the 
number of animal pairs. The legend given pertains to all graphs. Reductions in Tfrc and Ftl1 
transcripts were mainly seen in stria vascularis. The reduction in Tfrc transcripts is consistent 
with an elevated pool of free Fe and Aco1-regulated degradation of Tfrc mRNA and the 
reduction in Ftl1 transcripts is consistent with a reduced capacity to sequester Fe and Fe-
mediated free radical stress.   
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Figure 3.6: Quantification of proteins involved in Fe metabolism and total iron.   
(A-B) Transferrin (Trf) and transferrin receptor (Tfrc) were quantified relative to actin in stria 
vascularis and in the preparation of spiral ligament of Slc26a4+/- and Slc26a4-/- mice at age P35.  
Representative western blots and data summaries are shown. Significant changes are marked (*) 
and numbers next to the bars represent the number of blots. Changes in protein expression were 
seen in stria vascularis but not in the preparation of spiral ligament. (C) Tissue-Fe was 
quantified in stria vascularis and spiral ligament of Slc26a4+/- and Slc26a4-/- at age P10. No 
difference was found in tissue-Fe. The increase in Trf protein expression and the reduction in 
Tfrc protein expression is consistent with Fe-mediated free radical stress. 
Tissue-Fe was measured at age P10, before the onset of hearing, in stria vascularis and 
the spiral ligament preparation of Slc26a4+/- and Slc26a4-/- mice (Fig. 3.6). No difference in 
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Tissue-Fe was found in stria vascularis and spiral ligament of Slc26a4-/- compared to Slc26a4+/- 
mice.   
The changes in the transcript and protein level expression of Trf and Tfrc indicate Fe-
mediated oxidative stress in the stria vascularis of Slc26a4-/- mice. The reduction in Ftl1 
transcripts is consistent with a reduced capacity to sequester Fe and weakened defenses against 
oxidative stress. 
Western blot for Kcnj10 protein in stria vascularis  
Before evaluating the effect of oxidative and nitrative stress on Kcnj10 protein 
expression, the specificity of Kcnj10 antibodies was evaluated. Western blots revealed a 
considerable interexperimental variability in the pattern of bands and smears detected by anti-
Kcnj10 antibodies. Reprobing individual blots with two different anti-Kcnj10 antibodies, one of 
which was a monoclonal, revealed highly similar patterns of bands and smears (Fig. 3.7A vs. 
3.7C and 3.7D vs. 3.7F). Differences in the pattern of bands and smears was a function of the 
protein extraction method. The interexperimental variability, however, was encountered with all 
methods of protein extraction (compare Fig. 3.7C and 3.7D). Immunoprecipitation with the 
mouse monoclonal and detection with the rabbit polyclonal antibody revealed monomers of 
Kcnj10 at ~40 kDa as well as higher molecular weight bands and smears (Fig. 3.7G). This 
observation confirmed that the mouse monoclonal and the rabbit polyclonal antibody recognized 
the same protein in samples from stria vascularis.   
Further, incubating the primary antibody with a blocking peptide 
(KLEESLREQAEKEGSALSVR) resulted in the loss of all bands and smears (Fig. 3.7H and 
3.7I). In this experiment, a single lane of a blot was probed for Kcnj10 protein using the rabbit 
polyclonal antibody, then stripped and cut into two pieces that were reprobed for Kcnj10 in the 
absence and presence of blocking peptide. The cut pieces were rejoined for detection. This 
experimental protocol was chosen to unambiguously demonstrate that the addition of blocking 
peptide is sufficient to prevent detection of Kcnj10. Taken together, these data verify that the 
rabbit polyclonal and the mouse monoclonal antibody detect Kcnj10 and that Kcnj10 in stria 
vascularis exists as monomers (~40 kDa),  as well as in variable higher molecular weight 
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complexes. In subsequent experiments both smears and bands were regarded as Kcnj10 protein 
and quantification of expression was based on integrals of staining as shown in Fig. 3.2.   
The variability in the pattern of Kcnj10 expression is likely due to the interaction with the 
dystrophin glycoprotein complex. This complex contains proteins that greatly vary in their 
mobility patterns due to variable glycosylations and stoichiometries. Kcnj10 protein has been 
shown to be associated with the dystrophin glycoprotein complex in brain and retina and with 
aquaporin 4 in retina (6; 7). Moreover, ubiquitination may contribute to the observed smears. 
Progressive loss of Kcnj10 expression in the stria vascularis of Slc26a4-/- mice 
Protein expression of Kcnj10 was quantified in stria vascularis before the onset of 
hearing (P10 and P11) and after the onset of hearing (P13 and P15) (Fig. 3.8). As expected stria 
vascularis of Slc26a4+/- mice maintained and stria vascularis of Slc26a4-/- mice progressively lost 
the expression of Kcnj10 protein. These results are consistent with previous studies showing loss 
of Kcnj10 protein expression at P15 by immunohistochemistry and the loss of endocochlear 
potential (44). The loss of Kcnj10 protein expression occurs at a time point when the stria 
vascularis of Slc26a4-/- mice is under increased oxidative and nitrative stress. This finding 
suggests that increased oxidative and/or nitrative stress contributes to the loss of Kcnj10 protein 
expression in the stria vascularis of Slc26a4-/- mice. 
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Figure 3.7: Western blot for Kcnj10 protein in stria vascularis.   
(A-C) Protein was extracted from stria vascularis using three different methods and first probed 
for Kcnj10 with a mouse monoclonal antibody. This blot was stripped and reprobed for Kcnj10 
with a rabbit polyclonal antibody. Note that the pattern of staining varied with the method of 
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extraction but not with the antibody used for probing (compare A and C). (D-F) Similar 
experiments were performed in reverse order. Protein was extracted from stria vascularis using 
three different methods and first probed for Kcnj10 with a rabbit polyclonal antibody. The blot 
was then stripped and reprobed for Kcnj10 with a mouse monoclonal antibody. Note that 
considerable interexperimental variability in the pattern of bands and smears was encountered 
(compare C and D) but that the little variability was seen with the different antibodies (compare 
D and F). (G) Protein lysate from stria vascularis was immunoprecipitated with mouse 
monoclonal antibody for Kcnj10 and the resulting western blot was probed with a rabbit 
polyclonal antibody for Kcnj10. Note that a monomeric form of Kcnj10 (~40 kDa) and 
complexes that resulted in bands and smears of higher molecular weight were observed by 
immunopreciptation as well as by western blotting of whole cell lysates (compare A and G). (H-
I) A single lane containing stria vascularis protein was probed for Kcnj10, stripped, cut into two 
pieces (indicated by ) and probed again for Kcnj10 in the presence and absence of blocking 
peptide. These experiments confirmed that western blot for Kcnj10 in stria vascularis have both 
smears and bands. 
 
Figure 3.8: Quantification of Kcnj10 protein expression in native stria vascularis. 
Levels of Kcnj10 protein were quantified against tubulin at P10, P11, P13 and P15.  Significant 
changes between corresponding time points are marked (*) and numbers next to the bars 
represent the number of experiments. Kcnj10 expression was progressively lost from the stria 
vascularis of Slc26a4-/- mice. The loss of Kcnj10 expression in native tissue that is under the 
influence of oxidative/nitrative stress supports a role for oxidative/nitrative stress mediated loss 
of Kcnj10 expression. 
Protocol development for organ culture of stria vascularis 
A previous study has shown that stria vascularis in organ culture is poorly preserved and 
shows signs of degeneration in strial marginal and intermediate cells within 5 days (2). The 
degeneration of  stria vascularis could be due to low apical concentration of K+ in organ culture 
that would lead to elevated rates of K+ secretion from strial marginal cells (43). Increased ion 
transport rates would increase ATP consumption, ATP production and thereby enhance 
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mitochondrial stress (25). Furosemide and furosemide analogs have been shown to reduce ATP 
consumption and inhibit K+ secretion by strial marginal cells (23; 43). Reduced ATP 
consumption would reduce ATP production and thereby lower oxidative stress. Therefore 
furosemide supplementation might be useful in preserving the integrity of stria vascularis in 
organ culture. Stria vascularis was cultured in media with/without furosemide for 0, 1, 3 and 5 
days and evaluated for viability by quantifying the levels of tubulin. In the absence of furosemide 
tubulin expression was gradually lost. In the presence of furosemide stria vascularis could be 
cultured for at least 5 days (Fig. 3.9). Therefore to evaluate the expression of Kcnj10 in organ 
culture, stria vascularis was cultured in media supplemented with furosemide.  
 
Figure 3.9: Quantification of tubulin or actin protein expression in organ culture of stria 
vascularis.   
(A-B) Levels of tubulin or actin were quantified in P10 stria vascularis of Slc26a4+/- mice at 0, 1, 
3 and 5 days in organ culture. Data are presented as percent of tubulin or actin protein at 0 day 
of culture, which corresponds to age P10. Significant changes between corresponding time 
points are marked (*) and numbers next to the bars represent the number of experiments. 
Tubulin or actin expression was gradually lost in organ culture of stria vascularis in the absence 
of furosemide (FUR). Stria vascularis can be cultured for at least 5 days when the media is 
supplemented with 500 µM furosemide (FUR). 
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Similar expression of Kcnj10 in organ culture of Slc26a4-/- and Slc26a4+/- mice 
Stria vascularis from P10 Slc26a4-/- and Slc26a4+/- mice, were cultured. Protein 
expression of Kcnj10 was quantified in organ culture at 1, 3 and 5 days, corresponding to the 
time points of measurements in native tissue at P11, P13 and P15. Under conditions of equal 
oxidative stress in organ culture, stria vascularis of Slc26a4-/- mice was able to maintain Kcnj10 
expression at a level similar to Slc26a4+/- mice (Fig. 3.10). These observations suggest that 
oxidative stress mediates the loss of Kcnj10 expression in the native tissue.  
 
Figure 3.10: Quantification of Kcnj10 protein expression in organ culture of stria 
vascularis.   
Levels of Kcnj10 protein were quantified against tubulin in P10 stria vascularis of Slc26a4+/- 
and Slc26a4-/- mice at 0, 1, 3 and 5 days in organ culture. Significant changes between 
corresponding time points are marked (*) and numbers next to the bars represent the number of 
experiments. In contrast to native stria vascularis shown in Fig. 9, Kcnj10 expression level in 
organ culture (shown here) followed the same trend in Slc26a4+/- and Slc26a4-/- mice. Similar 
levels of Kcnj10 expression in stria vascularis of Slc26a4+/- and Slc26a4-/- mice under conditions 
of equal oxidative challenge in organ culture conditions supports oxidative stress mediated loss 
of Kcnj10 expression.  
Loss of Kcnj10 protein expression under oxidative and nitrative stress 
The effect of oxidative and nitrative stress on protein expression of Kcnj10 was evaluated 
in an heterologous expression system (Fig. 3.11). Cells were transfected with a vector that 
contains Kcnj10-GFP-Export-sequence. This plasmid was used in our study because the 
localization of Kcnj10 to plasma membrane in native tissues is lost under cell culture. However, 
insertion of the ER export sequence for Kir2.1 into the C-terminal of Kcnj10 enables it to 
translocate to the plasma membrane (39). Cells were treated with 500 µM furosemide to replicate 
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the conditions present in organ culture. Oxidative stress was induced by incubation with 10 µM 
H2O2. Further, oxidative and nitrative stress was induced by incubation with 1mM SIN-1.  SIN-1 
releases equimolar amounts of O2•- and •NO that react to produce peroxynitrite (27). Kcnj10 
expression was reduced in cells treated with SIN-1 but not in cells treated with H2O2. No 
significant change was found in the expression levels of tubulin suggesting that the observed 
differences in Kcnj10 expression are not due to cell death or degeneration. SIN-1 mediated loss 
of Kcnj10 suggests that free radical stress comprising of both oxygen and nitrogen radicals is 
capable of reducing Kcnj10 expression. It is conceivable that observed loss of Kcnj10 expression 
in stria vascularis of Slc26a4-/- mice is due to the combined effect of oxidative and nitrative 
stress. 
Discussion 
The most salient findings of the present study are that 1) Free radical stress is increased in 
stria vascularis of Slc26a4-/- mice as early as P10, which is before the onset of hearing; 2) Kcnj10 
expression is lost progressively in the stria vascularis of Slc26a4-/- mice; 3) Under conditions of 
equal oxidative stress, stria vascularis of  P10 Slc26a4-/- and Slc26a4+/- mice have a similar 
pattern of expression in organ culture; 4) Kcnj10 expression is reduced under free radical stress 
in cell culture. These results suggest that free radical stress is involved in the etiology of hearing 
loss in Pendred syndrome.  
Free radical stress that exceeds the capacity of defense mechanisms has been implicated 
in inner ear pathogenesis including acoustic trauma and drug-induced ototoxicity (17; 33). Stria 
vascularis is prone to free radical stress due to its high metabolic activity and dense vascular 
system (25). Oxygen free radical O2•- is a product of energy metabolism in the mitochondria and 
the nitrogen free radical •NO is generated by nitric oxide synthase in the endothelial cells of stria 
vascularis. The reaction between O2•- and •NO produces peroxynitrite (ONOO-). ONOO- 
decomposes to form the very aggressive nitrate radical (•NO2), that causes nitration of proteins.  
The formation of •NO2 from ONOO- is facilitated under acidic conditions or in the presence of 
CO2 (5; 24).  The sensitivity of Kcnj10 protein expression to free radical stress and the presence 
of oxidative and nitrative stress in stria vascularis suggest that free radical stress is responsible 
for the loss of Kcnj10 in Pendred syndrome.   
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Figure 3.11: Quantification of Kcnj10 protein expression under free radical stress.   
(A-B) Levels of Kcnj10 protein were quantified against tubulin in cell culture under the influence 
of 10 µM H2O2 and 1 mM SIN-1. Data are presented as percent of Kcnj10 expression in control 
samples.  Decrease in the expression of Kcnj10 protein was found in SIN-1 mediated oxidative 
and nitrative stress but not in H2O2 mediated oxidative stress. No significant change was found 
in the expression levels of tubulin between control and H2O2 or SIN-1 treatments. The loss of 
Kcnj10 expression under free radical stress provides with a mechanism for the observed loss of 
Kcnj10 in the stria vascularis of Slc26a4-/- mice. 
Reduction of Kcnj10 protein expression under free radical stress is a pathobiologic 
mechanism that is not limited to Pendred syndrome. Loss of Kcnj10 under free radical stress is 
also implicated in other disease models. Kcnj10 protein expression, unlike the expression of 
other K+ channels, is reduced in the retina after ischemia-reperfusion injury, an insult that is 
associated with oxidative stress (19). Furthermore, mice expressing a mutant superoxide 
dismutase (SOD1-G93A) have increased oxidative stress and reduced expression of Kcnj10 
protein in spinal cord tissues (1; 22). 
 The origin of increased free radical stress in stria vascularis may be related to the 
enlarged endolymphatic volume or the acidified endolymphatic pH of Slc26a4-/- mice. 
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Enlargement of the cochlear and vestibular endolymphatic compartments develop in Slc26a4-/- 
mice prenatally after embryonic day 13 (E13), when the onset of pendrin expression fails to 
occur in Slc26a4-/- mice (12). Shortly after birth, the composition of endolymph changes from a 
Na+ rich fluid to a K+ rich fluid. The onset of K+ secretion occurs at P3 (3; 45).  K+ is secreted by 
stria vascularis and the rate of K+ secretion is controlled by the endolymphatic K+ concentration 
(41; 43). Enlarged endolymphatic spaces with an inherently less favorable surface-to-volume 
ratio may require larger rates of K+ secretion to offset leakage and maintain the normal high 
endolymphatic K+ concentration found in Slc26a4-/- mice (42). Higher rates of K+ secretion can 
be associated with higher rates of oxidative stress since metabolism and ATP production in stria 
vascularis are tightly linked to the rate of ion transport (23; 25). It is conceivable that the onset of 
oxidative stress in stria vascularis coincides with the onset of K+ secretion at P3, which is prior to 
the onset of Kcnj10 expression and rise of endocochlear potential  at P8 and the onset of hearing 
at P12 (3; 18; 35; 44). 
Acidification of endolymph was observed in Slc26a4-/- mice at P10 and older ages (28; 
44). Acidification could contribute to free radical stress in stria vascularis if the lowered pH of 
endolymph would decrease the cytosolic pH of the adjacent stria marginal cells that are the most 
likely source of O2•-. The cytosolic pH could induce oxidative stress by enhancing the stability of 
•OH- and by promoting the formation of the aggressive •OH- , •NO2 from O2•- and •NO (5; 10).  
In conclusion, the data demonstrate that loss of pendrin leads to free radical stress in stria 
vascularis and that free radical stress is sufficient to cause the loss Kcnj10 expression. The loss 
of Kcnj10 expression in stria vascularis leads to the loss of the endocochlear potential and the 
failure to develop hearing in the mouse model of Pendred syndrome.   
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CHAPTER 4 - The Slc26a4-/- mice has no apparent thyroid 
dysfunction  
 
 
 
 
 
 
 
These data will be submitted as part of an article to a peer reviewed journal. 
Ruchira Singh, Christa Linsenmeyer, Kazuhiro Nakaya, Peying Fong, Daniel Marcus, and 
Philine Wangemann 
Loss of pendrin in the mouse acidifies luminal pH of thyroid follicles but does not 
alter thyroxine production. 
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Abstract 
Pendred syndrome is caused by mutations in the anion exchanger pendrin (SLC26A4) and 
is characterized by deafness, post-pubertal goiter and iodide organification defects. Studies were 
performed on thyroids from Slc26a4+/- and Slc26a4-/- mice at various ages: postnatal days 10 
(P10), P15 (corresponding to the time point of maximal thyroid gland activity), P30 (post-
weaning) and P80 (young adults). Global gene expression levels in the thyroid were evaluated by 
gene arrays performed at P15. Thyroxine (T4) levels in the serum were quantified by 
immunoassay. Gene expression was quantified by qRT-PCR. Western blotting was used to 
evaluate the expression of two proteins involved in thyroid hormone synthesis, Tpo and Duox1, 
as well as the chloride channel, ClC-5, oxidized proteins, eNOS and proteins involved in iron 
metabolism. Nitrated and oxidized proteins were quantified by ELISA. Total iron was measured 
by ferrozine spectrophotometry.  Slc26a4 mRNA expression was modest in the thyroid of 
Slc26a4+/- mice at all ages. Decreased levels of nitrated proteins were observed in the thyroid of 
Slc26a4-/- mice at P35. Between the Slc26a4+/- and Slc26a4-/- mice: a) no differences in the 
serum T4 levels were observed, b) no differences in the expression of Tpo and Duox1 were 
observed and c) no differences in the levels of oxidized proteins were observed. The absence of 
elevated levels of oxidized proteins suggests that increased oxidative stress is not present in the 
thyroid of Slc26a4-/- mice. The low expression of Slc26a4 in mouse thyroid and the normal 
thyroid gland function in the Pendred syndrome mouse model suggests a distinction between the 
roles of pendrin in murine and human thyroids. 
Introduction 
Pendred syndrome is an inherited autosomal recessive condition that primarily affects the 
thyroid and the inner ear. It is characterized by a positive perchlorate discharge test, goiter, and 
prelingual sensorineural deafness (6; 15; 19). Pendred syndrome is caused by loss-of-function 
mutations in the gene SLC26A4, which encodes pendrin. Pendrin is primarily expressed in the 
inner ear, the thyroid  and the kidney (10; 24; 29). In the thyroid, pendrin localizes to the apical 
membrane of thyrocytes and mediates iodide transport (9; 24; 32). Pendrin has been 
hypothesized to play a role in iodide organification by transporting iodide to the follicular lumen 
 89
(4). Therefore, lack of pendrin function has been suggested to limit the iodination of 
thyroglobulin, thereby affecting the synthesis of thyroid hormone (9; 15; 26).   
 Clinical studies suggest a role for pendrin in thyroid hormone metabolism. Patients with 
non-functional pendrin can present with goiter, which can be either hypothyroid or euthyroid. 
Moreover, mutations in Slc26a4 have been found in congenital hypothyroidism (2). Decreased 
expression of proteins that are involved in thyroid iodide metabolism, including pendrin, has 
been shown in thyroid cancer in humans (7; 27; 31). Thyroid carcinomas have also been reported 
in patients with Pendred syndrome (1; 3; 18).  
In the mouse, the thyroid gland activity peaks around postnatal day 15 (P15) (5). 
However, a study that investigated the thyroid histology and serum T3, T4 and TSH levels in 
adult mice identified no differences between  Slc26a4+/+ and Slc26a4-/- mice (8).  Because the 
previous study was carried out on adult mice, we were prompted to re-evaluate the thyroid 
pathology in thyroid of Slc26a4-/- mice in a developmental study (9; 25). Thus, the first aim of 
the present study was to determine the time course of Slc26a4 expression in the mouse thyroid 
and to evaluate the effect of absence of pendrin on the expression of genes/proteins involved in 
the synthesis of thyroid hormone and on serum T4 levels.  
Pendrin-mediated iodide/Cl- exchange in the apical membrane of the thyrocyte requires 
the presence of Cl- in the follicular lumen. It has been suggested that the Cl- channel, ClC-5, may 
assist in Cl- cycling by transporting Cl- into the follicular lumen.  If Cl- transport by ClC-5 and 
iodide transport by pendrin are a coupled mechanism, it is conceivable that lack of pendrin will 
have an effect on the expression of ClC-5. In one study, Clcn5-/- (Clcn5 encodes ClC-5) mice 
have been shown to develop euthyroid goiter that correlates with delayed iodide organification 
and reduced pendrin expression (30). The second aim of this study was to determine whether 
absence of pendrin affects ClC-5 protein expression in the mouse model of Pendred syndrome.  
The third aim of this study was to address whether free radical stress and iron metabolism 
are altered in the thyroid of Slc26a4-/- mice. Absence of pendrin is associated with increased free 
radical stress and altered iron metabolism in the stria vascularis of Slc26a4-/- mice(28), raising 
the possibility that it also may lead to increased oxidative stress in the thyroid gland. This is 
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particularly feasible, given that hydrogen peroxide (H2O2), a well known oxidant, is involved in 
the process of thyroid hormone synthesis (16; 21). Indeed, cumulative oxidative stress in the 
thyroid could underly the goiter formation and thyroid carcinomas observed in human patients 
with Pendred syndrome (1; 14; 22).  
Methods 
Animal use 
The Slc26a4-/- and Slc26a4+/- mice used in the experiments were raised in a colony at 
Kansas State University, established with breeders kindly provided by Dr. Susan Wall (Emory 
University, Atlanta, GA). Deeply anesthetized mice (tribromoethanol, 560 mg/kg, i.p.) were 
sacrificed either by decapitation or by transcardial perfusion with Cl--free solution (150 mM Na-
gluconate, 4 mM Ca2+-gluconate, 5 mM glucose 1.6 mM K2HPO4, 1 mM MgSO4, 0.4 mM 
KH2PO4, pH 7.4) and dissection was carried out in the same solution at -10 °C. All procedures 
performed on animals were approved by the Institutional Animal Care and Use Committee of 
Kansas State University. 
Gene array 
Total RNA was isolated from the thyroid of three P15 Slc26a4-/- and Slc26a4+/- mice 
(RNeasy micro, Qiagen, Valencia, CA, USA) and stored at -80 °C until further processing. RNA 
was processed at the Gene Expression Facility at Kansas State University. A total of six arrays 
were run from sex-matched littermates. Three chips, each, hybridized with cDNA from thyroids 
of Slc26a4+/- and Slc26a4-/- mice, were compared. RNA was amplified to produce cDNA, which 
was fragmented, biotinylated and hybridized to high-density oligonucleotide gene chips 
(Ovation™ RNA Amplification System V2, Cat # 3100-12, NuGen, San Carlos, CA  and FL-
Ovation™ cDNA Biotin Module V2, Cat # 4200-12, NuGen; mouse 430 2.0 gene chip, Cat # 
900496, Affymetrix, Santa Clara, CA, USA). Gene array data were analyzed using commercial 
software (GCOS, Affymetrix) and with custom-written macros (Excel, Microsoft, Redmond, 
WA, USA), as described previously (13). Present/absent calls were used to determine the 
expression, and averaged signal intensities (average of data obtained from three chips) were used 
to determine changes in expression levels. 'Intensity' for gene array data from Slc26a4+/- and for 
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Slc26a4-/- samples represents averages of data from one or more probes. For example, the gene 
Tg is represented on the chip by two probes. Present calls (P) were summarized for all three 
chips. For example, 6/6 indicates that this gene was called present by all 6 probes (2 × 3 = 6); 4/6 
indicates that the gene is represented by 2 probes on the 3 chips (2 × 3 = 6) and that the gene was 
called present by 4 of the 6 probes. Ratios of intensity values (Slc26a4-/- to Slc26a4+/-) were 
calculated for each probe and averaged. 
Quantitative RT-PCR 
Total RNA was isolated from the thyroid (RNeasy micro, Qiagen) and kidney (RNeasy 
mini, Qiagen) of sex-matched Slc26a4+/- and Slc26a4-/- littermates and stored at -80 °C until 
further processing. Real time RT-PCR in the presence of SYBR green (Molecular Probes, 
Eugene, OR) was carried out in 96-well plates (QuantiTect SYBR Green RT-PCR Kit Cat# 
204243, Qiagen, Valencia, CA; iCycler, BioRad, Hercules,CA) using gene specific primers 
(Table. 4.1).   
Table 4.1: Gene specific primers 
Gene Primers Product size 
18S  gag gtt cga aga cga tca ga (sense) 
gtt ctt agt tgg tgg agc ga (antisense) 316 bp 
Slc26a4  tcg gaa cat caa gac aca tc (sense)  
acc tca cta tga atc caa tct g (antisense) 252 bp 
Ferritin heavy chain  (Fth) ttt gag cct gag ccc ttt (sense) 
tca aag aga tat tct gcc atg c (antisense) 706 bp 
Actb gga cct gac aga cta cct c (sense)  
tcg ttg cca ata gtg atg ac (antisense) 210 bp 
The RT-PCR plate was set up by programming an automatic pipetting station (Biomek 
NXp, Beckman Coulter, Fullerton, CA). RT-PCR was performed as described previously (28). 
Single product amplification was verified by gel electrophoresis and the identity of the product 
was confirmed by sequencing. The number of template molecules (T) was calculated according 
to the following formula: T = 10^ log (number of molecules at Ct) / (PCR efficiency^Ct), where 
Ct represents the cycle at which the fluorescence of the product molecules reached a set 
threshold. Samples that failed to reach the set threshold within the 40 cycles of PCR were 
assigned a default Ct value of 40. The number of molecules at Ct was calibrated by amplifying 
known numbers of 18S rRNA molecules. The content of 18S in total RNA was estimated under 
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the assumption that total RNA consists of 90% 18S and 28S rRNA.  PCR efficiency was 
obtained from the slope of the log-linear phase of the growth curve (20). 
Serum T4 measurements 
Blood samples were collected by cardiac puncture, transferred into microcentrifuge tubes 
and allowed to clot for 30 min at room temperature. The clotted samples were centrifuged at 
1500 rpm for 10 min at room temperature. The serum was collected and centrifuged again at 
1500 rpm for 10 min at room temperature. The collected supernatant was stored at -20 °C until 
further processing. The total serum T4 was measured by a chemiluminescent enzyme 
immunoassay (Immulite® total T4, Siemens Healthcare Diagnostics, Deerfield, IL) according to 
the manufacturer’s instructions. 
Isolation of protein 
Freshly dissected thyroids were transferred into microcentrifuge tubes and excess Cl--free 
solution was removed. Freshly dissected spleens were flash-frozen in liquid nitrogen, then 
pulverized. Proteins from both tissues were extracted by adding 30 µl of Tris-Triton buffer (50 
mM Tris, 150 mM NaCl, 1% Triton-X) and bath sonicated for 30 min at 0 °C (Fisher Scientific, 
Pittsburgh, PA). The samples were centrifuged at 14,000 rpm for 10 min at 4 °C. The 
supernatant fractions were collected  and either used immediately or stored at -80 °C.   
Quantification of nitrated proteins  
The level of nitrotyrosine in isolated proteins was quantitated by two different 
immunoabsorbent assays (Cat # HK501, Cell sciences, Canton, MA; Cat #17-376, Millipore, 
Billerica, MA) according to the manufacturers’ instructions. (The total protein content of the 
sample was measured (NanoOrange protein quantitation kit, Cat # N666, Invitrogen, Carlsbad, 
CA). Differences in the amount of nitrotyrosine were evaluated by comparison of nitrated protein 
content to the total protein content. 
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Quantification of oxidized proteins 
Two different techniques were used to quantitate the oxidized proteins in tissue samples. 
Oxyblots: Carbonyl groups of oxidized proteins were derivatized with dinitrophenylhydrazine 
(Oxyblot Kit, Cat # S7150, Millipore,) to form denitrophenylhydrazone (DNP). DNP-labeled 
proteins were separated by SDS gel electrophoresis (5 µl/lane) and detected in western blots.  
Procedures were carried out according to the manufacturer’s recommendations. Differences in 
the presence of oxidized proteins were evaluated by comparison to the expression of actin or 
GAPDH.  ELISA: Protein was isolated and the level of oxidized proteins was quantified by an 
immunoabsorbent assay (Cat # STA-310, Cell Biolabs, San Diego, CA;) according to 
manufacturer’s recommendation.  
Quantitative western blotting  
An equal volume of Laemmli buffer containing 5% β-mercaptoethanol was added to the 
protein samples. Protein samples were either incubated at 75 °C for 10 min or at 37 °C for 1 
hour. Protein samples (15 µl) were separated by SDS-PAGE (4-15% Tris-SDS Polyacrylamide 
Precast Gels, Cat # 161-1104, BioRad Laboratories, Hercules, CA). After separation, proteins 
were transferred to PVDF membranes (0.2 µm pore size, Cat # 162-0174, BioRad), blocked with 
5% dry milk in TBS-Tween (137 mM NaCl, 20 mM Tris-Cl, 0.1% Tween-20, pH 7.6) and 
probed with primary antibodies (rabbit anti-ClC-5, 1:1000, a gift from Professor Thomas 
Jentsch, FMP/ Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany; goat anti-Tpo, 
1:200, Cat # sc-48951, Santa Cruz Biotechnology, Santa Cruz, CA; goat anti-Duox1, 1:200, Cat 
# sc-49939, Santa Cruz Biotechnology; rabbit anti-Trf, 1:750, Cat #A76, Biomeda, Foster City, 
CA; mouse anti-Tfrc 1:2,000, Cat #13-6800, Zymed, San Francisco, CA; rabbit anti-eNOS, 
1:500, Cat # 610296, BD Biosciences, San Jose, CA; rabbit anti-actin, 1:1000, Cat # A2066, 
Sigma, St. Louis, MO; mouse anti-GAPDH, 1:300, Cat # MAB374, Chemicon International, 
Billerica, MA; rabbit anti-tubulin, 1:500, Cat # ab6046, Abcam Inc., Cambridge, MA). 
Membranes were washed 4x for 15 min each in TBS-Tween and incubated with the appropriate 
HRP-conjugated secondary antibodies (anti-rabbit, 1:5,000, Cat # 1858415; anti-mouse, 1:5,000, 
Cat # 1858416, Pierce, Rockford, IL; anti-rabbit, 1:5,000, Cat # anti-goat, 1:5,000, Cat # sc-
2033, Santa Cruz Biotechnology). After washing 4x for 15 min each in TBS-Tween, HRP was 
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detected by chemiluminescence (SuperSignal West Femto Maximum Sensitivity Substrate, Cat # 
34095, Pierce, Rockford, IL) using a camera-based imaging workstation (4000MM, Kodak). 
Membranes were stripped and reprobed with an antibody to a reference protein. Differences in 
protein expression were evaluated by comparison to the expression of actin, GAPDH or tubulin. 
Quantification of total tissue Fe content 
A ferrozine-based assay was modified and used for total iron measurement in the tissue 
(11). Iron measurement in thyroid: Each freshly dissected thyroid was transferred into a 
microcentrifuge tube and excess Cl--free solution was removed. Guanidine hydrochloride (2 µl) 
was added to the tissue and mixed by a pulse spin. After incubation for 45 min at 60°C, 2 µl of 
FAT solution (0.5 M ferrozine, 0.5 M ascorbic acid and 1 M Tris-Cl, pH 7) was added. After 
mixing by pulse-spinning, the tissue was incubated for 45 min at 60°C.  Absorbance at 562 nm 
of the supernatant was measured (ND1000, Nanodrop Technologies) and standards containing 
FeCl2 were processed in parallel. Measurements of the total iron (Tissue-Fe) are reported per mg 
of  wet tissue weight. Iron measurement on spleen: Freshly dissected spleens were flash-frozen 
in liquid nitrogen, then pulverized. Guanidine hydrochloride (100 µl) was added to the tissue and 
mixed by a pulse spin. After incubation for 45 min at 60°C, 100 µl of FAT solution was added. 
Mixing was facilitated by a pulse spin and the tissue was incubated for 10 min at room 
temperature. Absorbance at 562 nm was measured in the supernatant of the 200 µl sample 
(ND1000, Nanodrop Technologies) and standards containing FeCl2 were processed in parallel. 
Measurements of the Tissue-Fe are reported per mg of wet tissue weight.   
Statistical analysis 
Data for the quality metrics on the gene array experiment are expressed as mean ± S.D. 
For all other experiments, data are reported as mean ± sem. Data throughout the manuscript were 
compared by unpaired t-test. Significance was assumed at P < 0.05. 
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Results 
Slc26a4 transcript  expression does not correlate  with the thyroid gland activity 
To determine whether pendrin expression correlates with the thyroid gland activity, the mRNA 
expression of Slc26a4 in the mouse thyroid was evaluated at various ages (Fig. 4.1). RNA was 
isolated from two pendrin-expressing tissues, thyroid and kidney, of Slc26a4+/– mice at the 
following ages: P10, P15, post-weaning mice (P30) and young adults (P80), and quantitative RT-
PCR was performed. As a quality control to ensure that the RT-PCR reaction worked and that 
sufficient level of RNA was present, transcript levels coding for ferritin heavy chain (Fth) and 
ActB were evaluated in parallel with Slc26a4 from the RNA samples. In comparison to the 
kidney where Slc26a4 was highly expressed at all ages, Slc26a4 expression in the thyroid of 
Slc26a4+/– mice was modest. No age dependence was observed in the expression pattern of 
Slc26a4 in either the thyroid or the kidney. Moreover, in a few experiments, Slc26a4 expression 
was below the level of detection in the thyroid samples since the fluorescence failed to reach the 
set threshold. Consistent with these results, Slc26a4 was called absent in the gene arrays 
performed on the thyroid of Slc26a4+/- mice. The relatively low and constant expression of 
Slc26a4 at all ages in the mouse thyroid indicates that Slc26a4 expression does not increase 
during the peak of thyroid gland activity at P15 in the mouse. 
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Figure 4.1: Slc26a4 mRNA expression in the thyroid is constant over various ages 
Transcripts coding for A) Slc26a4, B) Actb and C) ferritin heavy chain (Fth) were quantified 
relative to 18S RNA isolated from thyroid (TYR) and kidney (KID) from Slc26a4+/- mice at P10, 
P15, P30 and P80 (n=4).  Slc26a4 was highly expressed in the kidney and modestly expressed  
in the thyroid at all ages. Fth and Actb were highly expressed in the thyroid and kidney of 
Slc26a4+/- mice at all ages.  
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Lack of pendrin does not affect the expression of genes involved in thyroid hormone 
synthesis 
Gene array data from P15 Slc26a4+/– and Slc26a4–/– mice were analyzed to evaluate the 
expression of genes involved in thyroid hormone synthesis (Table 4.2). Gene array data analysis 
revealed no differences in the expression of Tg, Tpo, Duox2, Dio1 and Dio2 between the 
Slc26a4+/– and Slc26a4–/– mice. 
Table 4.2: Genes involved in thyroid hormone synthesis 
# Gene Description 
Slc26a4+/- 
Intensity 
P 
Slc26a4-/- 
Intensity 
P Fold Significance 
1 Tg Thyroglobulin 6,619 6/6 6,507 6/6 1.25 n.s
2 Tpo Thyroid peroxidase 2,737 3/3 2,967 3/3 1.08 n.s
3 Duox2 Dual oxidase 2 43 2/3 34 2/3 1.28 n.s
4 Dio1 Deiodinase 1 4,028 3/3 3,830 3/3 1.05 n.s
5 Dio2 Deiodinase 2 735 9/9 1114 9/9 1.56 n.s
6 Slc26a4 Pendrin 7 0/3 8 0/3 - -
7 NIS Sodium iodide symporter 1,157 6/6 935 6/6 1.12 n.s
For parameters ‘P’, and ‘Fold’ see section: Methods.Genearray.  Fold differences  are 
given when a gene was called Present (P) in Slc26a4+/- and  Slc26a4-/- samples in at least half of 
the available probes.  
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Western blots were performed to evaluate the protein levels of  Tpo and Duox1 in the 
Slc26a4+/– and Slc26a4–/– mice at various ages (Fig. 4.2). Although densitometry was not 
performed, visual inspection did not reveal obvious differences in the protein expression of Tpo 
and Duox1 between Slc26a4+/– and Slc26a4–/– mice. These observations suggest that the absence 
or presence of pendrin does not affect the expression of genes/ proteins that are involved in the 
synthesis of thyroid hormone. 
 
 
Figure 4.2: No visible difference between the protein expression of Tpo and Duox1  in the 
thyroid of  Slc26a4+/- and Slc26a4-/- mice.   
Representative western blots for Thyroid peroxidase (Tpo), dual oxidase 2 (Duox1) and  tubulin 
in thyroid of Slc26a4+/- and Slc26a4-/- mice at P10, P15, P30 and P80 (n=3).  Consistent with the 
gene expression data, no differences in the protein expression of Tpo and Duox1 were detected 
in the thyroid of Slc26a4-/- mice as compared to Slc26a4+/- mice. Data were collected by Christa 
Linsenmeyer and Ruchira Singh 
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Lack of pendrin does not affect serum T4 levels 
Fig. 4.3 shows a time course of serum T4 level as measured by immunoassay of the 
serum samples from Slc26a4+/– and Slc26a4–/– mice. No differences in the T4 levels in the serum 
of Slc26a4+/– and Slc26a4–/– mice were observed at any time point included in this study. These 
data are consistent with results from previous studies suggesting the lack of overt 
hypothyroidism in Slc26a4–/– mice (8). 
 
Figure 4.3: No difference in serum T4 levels is observed between Slc26a4+/- and Slc26a4-/- 
mice.   
Measurement of serum T4 levels in Slc26a4+/- and Slc26a4-/- mice at ages P5, P10 P15, P30 and 
~ P90.  Numbers next to the bars represent the number of observations.  No differences in the T4 
levels in the serum of  Slc26a4+/– and Slc26a4–/– mice were found at any age, indicating that 
Slc26a4–/– mice do not develop systemic hypothyroidism. Data were collected by Christa 
Linsenmeyer. 
 100
Lack of pendrin does not affect ClC-5 protein expression in the thyroid 
Clcn5-/- mice show selective loss of pendrin expression in the thyroid (30). This finding 
led us to investigate whether the knockout of pendrin affects ClC-5 protein expression. The 
expression of ClC-5 was compared between the Slc26a4+/– and Slc26a4–/– mice using western 
blots (Fig. 4.4). No difference in the expression of ClC-5 in the thyroids from Slc26a4+/– and 
Slc26a4–/– mice was found at any time point included in this study. This finding suggests that 
lack of pendrin does not affect the expression of ClC-5 in the thyroid.  
 
Figure 4.4: No visible difference is observed in the ClC-5 protein expression level in the 
thyroid of  Slc26a4+/- and Slc26a4-/- mice.   
Representative western blots for ClC-5 protein and tubulin in thyroid of Slc26a4+/- and Slc26a4-/- 
mice at P10, P15, P30 and P80 (n=3). Based on visual inspection, no difference in thyroid ClC-
5 protein expression was seen at any age in Slc26a4-/- mice as compared to Slc26a4+/- mice.   
Data were collected by Dr. Peying Fong, Christa Linsenmeyer and Ruchira Singh. 
Lack of pendrin leads to reduced nitrative stress in the thyroid 
The finding that free radical stress is increased in the stria vascularis of Slc26a4-/- mice 
led us to investigate oxidative and nitrative stress in other tissues (28). Oxidative stress was 
evaluated in: a) a pendrin-expressing tissue, thyroid, and b) a non-pendrin-expressing tissue, 
spleen. Oxidized proteins, using DNP-labeling of carbonyl groups by derivatization with DNPH, 
were detected by: a) western blot at P35 (Fig. 4.5A, 4.5B) and b) ELISA at P15 (Fig. 4.5C). Note 
that no labeling was observed in the absence of derivatization in western blot (Fig. 4.5A). No 
difference in the levels of oxidized proteins was found between the thyroids of Slc26a4+/– and 
Slc26a4–/– mice. It is important to note that two different techniques were used to quantitate 
oxidized proteins at P15 and P35. Although data from two different techniques cannot be 
compared, both data sets are presented. (The reason for using two different techniques at P15 and 
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P35 is due to the use of P35 mice for our initial experiments. In later experiments we decided to 
focus on P15, an age that corresponds to the maximal activity of thyroid gland.) 
 
Figure 4.5  The levels of oxidized proteins were not different in the thyroid of Slc26a4+/- and 
Slc26a4-/- mice.  
(A-B) Oxidized proteins were quantified against actin or GAPDH in thyroid and spleen from 
Slc26a4+/- and Slc26a4-/- mice at P35. Representative western blots and data summaries are 
shown. (C) Relative amount of oxidized protein was determined by ELISA in thyroids from 
Slc26a4+/- and Slc26a4-/- mice at  P15.  No difference in the levels of oxidized proteins was found 
between thyroid or spleen of Slc26a4+/- and Slc26a4-/- mice. 
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The protein expression of eNOS was evaluated by western blots in a developmental study 
(Fig. 4.6A, 4.6B). The amount of nitrated proteins in relationship to the total protein was 
quantified at P15 and P35 in the thyroid of Slc26a4-/- and Slc26a4+/- mice (Fig. 4.6C).  No 
difference in the levels of eNOS was found between the thyroid of Slc26a4-/- and Slc26a4+/- mice. 
Although Slc26a4+/– and Slc26a4–/– mice show similar levels of nitration at P15, nitration is 
reduced at P35 in  Slc26a4–/– mice, suggesting that thyroid of Slc26a4-/- mice experience reduced 
nitrative stress. It is conceivable that reduction of nitrative stress occurs between P15 and P35. 
 
Figure 4.6: The amounts of nitrated proteins in the thyroid of Slc26a4-/- mice were 
decreased in comparison to the thyroid of Slc26a4+/- mice.  
(A-B) Protein expression of eNOS was quantified relative to tubulin in thyroid of Slc26a4+/- and 
Slc26a4-/- mice at P10, P15 and P30. Representative western blots and data summaries are 
shown. No difference in eNOS expression was found between Slc26a4+/- and Slc26a4-/- mice at 
any age. (C) The level of nitrotyrosine by ELISA was quantified against total protein in thyroids 
from Slc26a4+/- and Slc26a4-/- mice at P15 and P35.  Significant changes are marked (*) and 
numbers next to the bars represent the number of observations. Reduced levels of nitrated 
protein were seen at P35 in the thyroid of Slc26a4-/- mice.  
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Lack of pendrin does not affect the expression of Trf and Tfrc in thyroid and spleen.  
The observation that the expression of genes involved in iron metabolism is altered in the 
stria vascularis of Slc26a4-/- mice led us to investigate the expression of Trf and Tfrc, two 
proteins involved in iron metabolism, in a pendrin-expressing tissue, thyroid, and in a non-
pendrin expressing tissue, spleen (28). Protein levels of Trf and Tfrc were quantified in the 
thyroid and spleen of Slc26a4+/- and Slc26a4-/- mice at P35 (Fig. 4.7A). Further, the tissue iron 
levels (Tissue-Fe) were measured at P15 corresponding to the time point of maximal activity of 
thyroid gland (Fig. 4.7B). No differences in protein expression of Trf and Tfrc were found in the 
thyroids and spleens of Slc26a4+/- and Slc26a4-/- mice at P35. No differences in tissue-Fe were 
found in the thyroids and spleens of Slc26a4-/- compared to Slc26a4+/- mice at P15.   
 
Figure 4.7: Tissue iron levels and protein expression of Trf, Tfrc was unchanged in the 
thyroid and spleen of Slc26a4+/- and Slc26a4-/- mice.    
(A) Transferrin (Trf) and transferrin receptor (Tfrc) were quantified relative to tubulin in 
thyroid and spleen of Slc26a4+/- and Slc26a4-/- mice at age P35. (B) Tissue-iron  was quantified 
in thyroid and spleen of Slc26a4+/- and Slc26a4-/- at age P15. Numbers next to the bars represent 
the number of observations.  No difference was found in tissue-Fe or the levels of  Trf and Tfrc 
between thyroid or spleen of Slc26a4+/- and Slc26a4-/- mice. 
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Discussion  
The most salient finding of the present study is that no difference between the thyroid 
gland function was observed between littermates of Slc26a4+/- and Slc26a4-/- mice. The inference 
that Slc26a4 expression is not essential for thyroid gland function is derived from the following 
observations: 1) Slc26a4 mRNA expression is very low in the mouse thyroid and its levels do not 
increase at the time point corresponding to maximal thyroid gland activity, 2) no observable 
effect of lack of pendrin is seen on the expression of genes involved in thyroid hormone 
synthesis and 3) serum T4 levels are unaffected in Slc26a4-/- mice.   
It is conceivable that the variability in thyroid phenotype between human patients and 
Slc26a4-/- mice is due to differences in Slc26a4 expression between humans and rodents. Slc26a4 
transcript is highly expressed in the human thyroid at levels much higher than in the kidney (9). 
In contrast, our results show very little Slc26a4 mRNA expression in the mouse thyroid at all 
time points, including those of maximal gland activity. Consistent with our finding, another 
group has reported that Slc26a4 mRNA expression in thyroids from adult mice is only 2% of the 
kidney expression (30).  
Pendrin in the thyroid has been implicated in iodide transport across the apical membrane 
of the thyrocytes (24; 32). Iodide organification defects are seen in human Pendred syndrome 
patients, and reduced expression of pendrin has been implicated as the cause of euthyroid goiter 
due to delayed iodide organification in Clcn5-/- mice (30). However, our current observations 
suggest that pendrin is not necessary for thyroid gland function, at least not in the 129Sv/Ev 
strain of mice. Two possible reasons for the presence of euthyroid goiter in Clcn5-/- mice could 
be that 1) although a lack of ClC-5 is associated with reduced pendrin expression, the euthyroid 
goiter observed in Clcn5-/- mice is caused by a different mechanism and 2) the two mouse strains, 
129Sv/Ev and C57BL/6J, respond differently to absence of pendrin in the thyroid gland. Pendrin 
has not been shown to transport iodide in vivo, which could imply that 1) the apical iodide 
transporter in the thyroid remains to be identified, 2) the apical iodide transporter differs between 
human (pendrin) and mouse thyroid (unidentified) or 3) an unidentified iodide transporter 
compensates for the absence of pendrin in the mouse thyroid. 
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The absence of Slc26a4 leads to increased free radical stress in the stria vascularis of 
Slc26a-/- mice (28). The absence of increased levels of free radical stress markers in the thyroid 
of Slc26a4-/- mice suggests that complete absence of Slc26a4 in itself may not be sufficient to 
cause free radical stress. Alternatively, it is possible that increased free radical stress is present in 
the thyroid but is restricted to a few cells and hence was not detected in analysis of whole tissue 
lysate.  
One of the consistent features of Pendred syndrome in human patients is deafness (12).  
Hypothyroidism at birth is known to lead to deafness. Since most Pendred syndrome patients are 
deaf at birth and mutations in Slc26a4 are found in congenital hypothyroidism, it difficult to 
completely rule out systemic hypothyroidism as the cause of deafness in Pendred syndrome (2). 
Our present finding that the overt hypothyroidism is not present in Slc26a4 -/- mice together with 
the fact that deafness is a consistent feature of Pendred syndrome mouse model establishes that 
absence of Slc26a4 in the cochlea is sufficient to affect hearing. However, it is still possible that 
lack of Slc26a4 leads to conditions of local hypothyroidism in the cochlea that could contribute 
to deafness in Pendred syndrome. Tissue-specific hypothyroidism limited to the cochlea has been 
demonstrated as the cause of deafness in Dio2-/- mice (17).  
The normal function of the thyroid gland in the Pendred syndrome mouse model and the 
difference in Slc26a4 expression between mouse and human thyroid suggest that pendrin has a 
different functional role in mouse and human thyroids. 
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